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CHAPTER I 
TOTAL SYNTHESIS AND BIOLOGICAL EVALUATION OF (+)-7-
BROMOTRYPARGINE 
1.1 Introduction 
Drug discovery based on natural products, and marine natural products in particular, 
has been a highly successful approach toward novel lead series and marketed therapeutics 
for both peripheral and central nervous system (CNS) disorders1,2.  With the recent decline 
in natural products research by the pharmaceutical industry3, academic labs such as our own 
have undertaken the task of synthesizing and evaluating small molecule natural products for 
therapeutic potential.  To that end, a number of marine natural products, such as aplysamine 
1.1,4 verogamine 1.2,5 conessine 1.36 and dispyrin 1.4,7,8 have  been shown to display both 
affinity for, and inhibition of the histamine subtype 3 (H3) receptor (Figure 1.1.1)9,10,11.  The H3 
receptor is a presynaptic autoreceptor within the Class A GPCR family, which also functions as a 
heteroreceptor modulating levels of neurotransmitters such as dopamine, acetylcholine, 
norepinephrine, serotonin, GABA and glutamate9,10,11.  As a result, the H3 receptor has garnered a 
great deal of interest from the pharmaceutical industry for the possible treatment of obesity, 
epilepsy, circadian arrhythmia, schizophrenia, Alzheimer’s disease, neuropathic pain and 
ADHD9,10,11. 
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Figure 1.1.1: Marine natural products 1.1 - 1.4 with significant affinity for, and inhibition of the 
H3 receptor. 
Basic Amine
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Figure 1.1.2: The refined H3 pharmacophore model, to which synthetic small molecule and 
natural product H3 antagonists conform. 
Importantly, conserved elements have been identified within small molecule H3 ligand 
scaffolds that have resulted in a highly predictive pharmacophore model, and many marine 
natural products conform to this model9,10,11.   This pharmacophore is best represented by 
generally linear structures featuring a basic amine situated on the western-most section of the 
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molecule.  An aliphatic spacer region connects the western amine to the core, which can feature a 
range of different functionalities including hydrogen bond donor groups, additional basic amines, 
lipophilic aromatic or saturated ring systems, and acidic moieties.   
-Carboline alkaloids are a prevalent class of biologically active natural products from 
marine organisms.  They exhibit diverse structural features and distinct neuropharmacological 
profiles12,13.  Our lab has worked extensively in this arena14,15, and we were attracted to a class of 
-carboline alkaloids represented by the trypargines 1.5-1.7 (Figure 1.1.3), as these alkaloids 
mapped well onto the H3 pharmacophore model and offered a synthetic challenge16,17.  Both 
trypargine 1.516 and 6-hydroxytrypargine 1.617 are highly toxic alkaloids.  (+)-7-Bromotrypargine 
1.7, was only recently isolated by Quinn and coworkers from the Australian marine sponge 
Ancornia sp., and found to possess antimalarial activity18.  6-Bromotyramine 1.8 was isolated 
along with 1.7 in similar quantities, and is believed to be a key biosynthetic precursor18.  Based 
on the neuropharmacological profiles of -carboline alkaloids, and the electron-deficient nature 
of 1.7, relative to the electron-rich congeners 1.5 and 1.6, which might diminish the cytotoxicity, 
the total synthesis of 1.7 and biological evaluation seemed warranted.  
 
Figure 1.1.3: Structures of the (+)-trypargines 1.5 - 1.7 and 6-bromotryptamine 1.8. 
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1.2 Retrosynthetic Analysis of (+)-7-bromotrypargine 
Our retrosynthesis of 1.7 (Figure 1.2.1) began by disconnecting the guanidine moiety, as 
it could easily be incorporated late in the synthesis.  We envisioned two approaches to cyclize the 
β-carboline C ring: either utilize the recently reported Brønsted-acid catalyzed, enantioselective 
Protio-Pictet-Spengler reaction19,20, or a Bischler-Napieralski reaction14, followed by an 
asymmetric Noyori transfer hydrogenation protocol21.  
 
Figure 1.2.1: Retrosynthetic Analysis of (+)-7-bromotrypargine 
1.3 Enantioselective Protio-Pictet-Spengler Route  
We viewed the enantioselective protio-Pictet-Spengler reaction as a more favorable route, 
as it would utilize newly developed chemistry to form the C ring and set the C-1 stereocenter in a 
single reaction, whereas the Bischler-Napieralski reaction/Noyori transfer hydrogenation route 
involved a two-step procedure and has been previously featured in other well established 
protocols15,21.   
1.3.1 Synthesis of 6-bromotryptamine 
As both envisioned routes toward 1.7 required the synthesis of 6-bromotyramine 1.8, our 
forward synthesis began with 6-bromoindole. As shown in Scheme 1.3.1.1, acid-mediated nitro 
olefination of 6-bromo-1H-indole 1.9, as prescribed by Büchi12, proceeded smoothly affording 
nitro olefin 1.10 in 98% yield.  Exhaustive reduction with LiAlH4 then provided natural 6-
bromotyramine 1.8 in 76% yield.   
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Scheme 1.3.1.1: Synthesis of 6-bromotryptamine 1.8. 
1.3.2 Synthesis of Key Aldehyde 1.13 
Key aldehyde 1.13 was synthesized in two steps starting from commercially available 4-
aminobutanol (Scheme 1.3.2.1). Phthalamide protection under microwave conditions proceeded 
smoothly, followed by Swern oxidation to yield the desired aldehyde 1.13.  
 
Scheme 1.3.2.1: Synthesis of key aldehyde 1.13. 
1.3.3 Synthesis of Asymmetric Pictet-Spengler Catalyst 
The Jacobsen thiourea asymmetric Pictet-Spengler catalyst was synthesized in two steps 
starting from N-methylanaline and N-Boc protected L-valine.  Standard EDC coupling conditions 
were employed, followed by acid mediated Boc group cleavage to render the free amine 1.16.  
Base induced thiourea formation from the corresponding thiocyanate 1.17 yielded the complete 
catalyst 1.18 in good yield (Scheme 1.3.3.1).  Optical rotation analysis confirmed that we had 
synthesized the correct enantiomer of the catalyst19.  
 6 
 
 
Scheme 1.3.3.1: Synthesis of the Jacobsen thiourea asymmetric Pictet-Spengler catalyst 
1.3.4 Protio-Pictet-Spengler Route 
With gram quantities of 1.8 and 1.13 in hand, we evaluated both the Jacobsen thiourea 
Brønsted-acid catalyzed, enantioselective Protio-Pictet-Spengler reaction19 as well as the Dixon 
chiral BINOL-derived phosphoric acid variation20 to produce the key, chiral -carboline core 1.19 
(Scheme 1.3.4.1).  
 
Scheme 1.3.4.1: Brønsted-acid catalyzed, enantioselective Protio-Pictet-Spengler approach. 
Interestingly, neither protocol afforded 1.19.  A range of different conditions were 
employed, including modifications to stoichiometric equivalents of starting materials and 
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catalysts, solvents, and reaction temperatures.  We found that conversion to 1.19 could be forced 
under both protocols (~80% yield) at temperatures above 50o C, however enantioselectivity 
eroded, with both catalyst systems yielding racemic mixtures.  We hypothesized that the electron-
withdrawing character of the bromine atom could be removing sufficient electron density from 
the indole system to prohibit nucleophilic attack onto the corresponding imine formed from the 
condensation reaction between 1.8 and 1.13.   
 
Scheme 1.3.4.2: Key nucleophilic attack by indole C-2 position. 
In order to test this hypothesis, an electron rich congener of 1.8, in the form of 6-
methoxytryptamine 1.20 was employed.  When 1.13 and 1.20 were combined under the 
optimized conditions reported by Jacobsen and coworkers, the reaction proceeded smoothly, 
providing 1.21 in good enatiomeric excess and conversion.   
 
Scheme 1.3.4.3: Electron-rich congener Protio-Pictet-Spengler reaction. 
With these data in hand, we concluded that the Brønsted-acid catalyzed, enantioselective 
Protio-Pictet-Spengler approach with the more electron deficient 1.8, was an intractable route 
toward the natural product.  Indeed, the original reports by Jacobsen and Dixon utilized only 
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electron rich substrates19,20.  Thus, our focus shifted towards a Bischler-Napieralski/Noyori 
asymmetric transfer hydrogenation approach15,21. 
1.4 Bischler-Napieraslki/Noyori Transfer Hydrogenation Route 
In order to proceed with the Bischler-Napieralski reaction, key acid 1.23 was prepared in 
98% yield by treating 4-aminobutanoic acid 1.22 with phthalic anhyride under microwave 
conditions (Scheme 1.4.1). Standard EDC/HOBT amide coupling conditions were then employed 
with 1.8 and 1.23, providing amide 1.24 as the cyclization precursor.   
 
Scheme 1.4.1: Phthalamide protection and amide coupling. 
1.4.1 Synthesis of Noyori Transfer Hydrogenation Catalyst 
The Noyori transfer hydrogenation catalyst was synthesized by heating (p-
Cymene)ruthenium dichloride dimer in isopropyl alcohol with N-((1R,2R)-2-amino-1,2-
diphenylethyl)-4-tosylate (Scheme 1.4.1.1)22.  
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Scheme 1.4.1.1: Synthesis of transfer hydrogenation catalyst 1.27. 
1.4.2 Bischler-Napieralski Reaction and Noyori Transfer Hydrogenation 
The Bischler-Napieralski reaction15,21 was facilitated by treatment of amide 1.19 with 
POCl3 in refluxing acetonitrile, yielding imine 1.20 in 88% yield.  Noyori asymmetric transfer 
hydrogenation with formic acid, triethylamine, and (S,S)-ruthenium catalyst 1.27 delivered the -
carboline core 1.19 in 80% yield and 90% ee, which we confirmed utilizing chiral SFC 
chromatography.  
 
Scheme 1.4.2.1: Bischler-Napieralski reaction / Noyori asymmetric transfer hydrogenation. 
1.5 Final Steps Toward 1.7 
After setting the stereocenter, we then removed the phthalimide protecting group with 
hydrazine to afford amine 1.29.  Guanidation and removal of the bis-Boc protecting groups 
proceeded in 84% yield over the three steps delivering, for the first time, (+)-7-bromotrypargine 
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1.7.   Synthetic 1.7 exhibited physical and spectroscopic data identical to that of natural 1.718, 
confirming the structure and absolute stereochemistry. Overall, the synthesis proceeds in 9 steps, 
8 steps longest linear sequence, in 40% overall yield which provided significant material to 
enable detailed biological evaluation. 
 
Scheme 1.5.1: Final steps to complete 1.7. 
1.6 Biological Evaluation of (+)-7-bromotrypargine 
In order to examine the effects of 1.7 and unnatural analogs at various therapeutic targets, 
we first addressed questions of general cytotoxicity.   
1.6.1 Cytotoxicity Screening 
 As 1.5 and 1.6 are highly toxic alkaloids, we first evaluated 1.7 in a standard cytotoxicity 
assay and found 1.7 to be non-toxic up to concentrations of 20 M, suggesting that the 
pharmacological profile of 1.7 might diverge from 1.5 and 1.623.  This surprising result led us to 
study 1.7 in our standard HCT116 colon carcinoma cell viability assay24,25.  Here as well, 1.7 had 
no effect on HCT116 cell viability after 48 hours.  In contrast, advanced intermediate 1.29, an 
unnatural analog of 1.7, displayed an IC50 value of 3 M in this assay, completely killing the cells 
after 48 hours.   
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Figure 1.6.1.3: BrdU Cell Proliferation Assay results with 1.7 (NP) and 1.29 (PC). Na Butyrate is 
a positive control for inhibition of cell proliferation. 
Collectively, these data informed us of two important  points: 1) the pharmacology of the 
more electron deficient (+)-7-bromotrypargine (1.7) is distinct from 1.5 and 1.6 and warranted 
further biological evaluation as it lacked toxicity, and 2) unnatural analog 1.29 possesses an 
intriguing pharmacological profile warranting the synthesis and characterization of additional 
unnatural analogs of 1.7. 
1.6.2 GPCR, Ion Channel, and Transporter Screens 
(+)-7-Bromotrypargine (1.7) was then evaluated in an external panel26 of  68 GPCRs, ion 
channels and transporters in radioligand binding assays in an attempt to identify discrete 
molecular targets with therapeutic relevance, a strategy that has been highly successful6,7.  In this 
instance, 1.7 was found to have a very clean pharmacological profile, affording significant 
percent inhibition of radioligand binding at only three targets: H3 (74% at 10 M), the Dopamine 
Transporter, DAT (81% at 10 M) and the norepinephrine transporter, NET (82% at 10 M).  
Interestingly, these are all targets for important pathologies of the central nervous system (CNS), 
and 1.7 did prove to possess activity at the H3 receptor as envisioned.  Indeed, 1.7 is now the fifth 
marine natural product with significant activity at H3, a target of interest for Alzheimer’s disease, 
schizophrenia, ADHD and other indications8,9,10.  Functional dose-response curves were 
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generated for the three targets in both binding (Ki) and functional (IC50) assays26, proving that 1.7 
both bound to, and inhibited, the three targets with modest potencies (Table 1.6.2.1).  
Table 1.6.2.1: Pharmacological profile of 1.7, radioligand binding and functional assay results. 
 
1.7 Unnatural Analog Development 
In order to optimize the H3 receptor and dual NET/DAT activity, we would need to have 
reliable chemistry to prepare unnatural analogs of 1.7 (Figure 1.7.1) in short order, while also 
removing functionality, such as the guanidine, that would limit brain penetration.   
 
Figure 1.7.1: Potential sites about 1.7 for differentiation in unnatural analog development. 
Thus, we piloted a number of ‘classical’ reactions (reductive amination, acylation, 
sulfonylation, Suzuki coupling, etc.) that are mainstays in the pharmaceutical industry en route to 
unnatural analogs of 1.7 (Scheme 1.7.1).  Prior to removal of the phthalamide moiety, the 
secondary amine 1.19 underwent a reductive amination reaction to provide tertiary amine 1.30 in 
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88% yield.  Removal of the phthalmide moiety liberated primary amine 1.31 that was smoothly 
acylated 1.32, sulfonylated 1.33 or guanidated 1.34 to afford unnatural analogs of 1.7 in excellent 
isolated yields (>85%). 
 
Scheme 1.7.1: Synthesis of unnatural analogs of 1.7 
1.8 Conclusion 
In summary, we completed the first total synthesis of (+)-7-bromotrypargine (1.7) in nine 
steps (8 steps longest linear sequence) in 40% overall yield from commercial materials.   In the 
course of this work, we found that the Brønsted-acid catalyzed, enantioselective Protio-Pictet-
Spengler reaction works well for electron-rich substrates, but fails for electron-deficient cores, 
and thus, was ineffective in accessing 1.7.  Biological evaluation of 1.7 and an advanced 
intermediate 1.29 proved very exciting, as 1.7 displayed divergent pharmacology from related -
carbolines 1.5 and 1.6. Additionally, we found that 1.29 was extremely cytotoxic in multiple non-
transformed and colon cancer cell lines.  Receptor profiling efforts identified 1.7 as a moderately 
potent, dual DAT/NET inhibitor, and only the second known compound and chemotype, to 
display such a pharmalogical profile devoid of SERT activity.  This finding was in addition to the 
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anticipated activity as an H3 antagonist, based on the H3 pharmacophore model.  The intriguing 
pharmacological profile then led us to explore chemistry to access unnatural analogs.  
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EXPERIMENTAL METHODS 
Synthesis: 
All reagents were purchased from Sigma‐Aldrich Corp., Matrix Scientific, Fisher 
Scientific, and Strem Corp., and were used without purification. Analytical thin‐layer 
chromatography (TLC) was performed on 250 μm silica gel plates from Sorbent Technologies. 
Visualization was accomplished via UV light, and/or the use of ninhydrin, 2,4-
dinitrophenylhydrazine, and potassium permanganate solutions followed by application of heat. 
Chromatography was performed using Silica Gel 60 (230‐400 mesh) from Sorbent Technologies 
or Silica RediSep Rf flash columns on a CombiFlash Rf automated flash chromatography system. 
All 1H and 13C NMR spectra were recorded on Bruker AV‐400 (400 MHz), DRX-500 (500 MHz) 
and AV-600 (600 MHz) instruments. Chemical shifts are reported in ppm relative to residual 
solvent peaks as an internal standard set to δ 7.26 and δ 77.16 (CDCl3), δ 3.31 and δ 49.00 
(CD3OD), and δ 2.50 and δ 39.52 (DMSO). Data are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = pentet br = broad, dd=doublet of 
doublets, dq=doublet of quartets, td = triplet of doublets, pd = pentet of doublets, m = multiplet), 
coupling constant (Hz), integration. Low resolution mass spectra (LCMS) were obtained on an 
Agilent 1200 LCMS with electrospray ionization. High resolution mass spectra (HRMS) were 
recorded on a Waters Qtof‐API‐US plus Acquity system with ES as the ion source. Analytical 
high pressure liquid chromatography (HPLC) was performed on an Agilent 1200 analytical 
LCMS with UV detection at 214 nm and 254 nm along with ELSD detection. Chiral separations 
were performed on a Thar Investigator II supercritical fluid chromatograph (SFC) utilizing 
Chiralcel® OD, OD‐Cl, OJ, and Chiralpak® IA columns. Optical rotations were acquired on a 
Jasco P‐2000 polarimeter at 23oC and 589nm. The specific rotations were calculated according to 
the equation [α]D 23 = (α/ l x c)	where l	is the path length in decimeters and c	is the concentration in 
g/100mL. 
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6-bromo-3-(2-nitrovinyl)-1H-indole (1.10). 
1-(Dimethylamino)-2-nitroethylene (1.6 g, 13.72 mmol) was dissolved in 20 mL trifluoroacetic 
acid and stirred 5 min.  6-Bromoindole (1.9) (3.23 g, 16.47 mmol) was dissolved in 15 mL 
dichloromethane and added to the stirring solution.  The mixture was stirred for 15 minutes at 
room temperature and monitored for loss of starting indole by thin layer chromatography.  After 
15 minutes, the reaction was transferred to a 1 L separatory funnel, rinsing with DCM, and 
quenched with 200 mL water.  The aqueous phase was extracted three times with DCM and the 
combined organic phase was dried over MgSO4, filtered, and concentrated onto 10 g silica.  The 
product was purified on silica (EtOAc/hexanes 1:2), yielded 3.61 g (98%) 1.10 as a yellow solid. 
1H NMR (600.1 MHz, d6-DMSO) δ (ppm): 8.39 (d, J = 13.5 Hz, 1H) 8.25 (s, 1H), 8.02 (d, J = 
13.5 Hz, 1H), 7.95 (d, J = 8.51 Hz, 1H), 7.71 (d, J = 1.75 Hz, 1H), 7.35 (dd, J = 1.85, 8.51 Hz, 
1H); 13C NMR (150 MHz, d6-DMSO) δ (ppm): 138.9, 137.1, 134.4, 132.3, 124.9, 124.1, 122.6, 
116.3, 115.8, 108.6; HRMS (TOF, ES+)  C10H8N2O2Br [M+H]+ m/z  266.9769, measured 
266.9769. 
 
6-bromotryptamine (1.8). 
A 250 mL schlenk flask equipped with a stir bar and septa was flame dried under vacuum.  
LiAlH4 (2.03 g, 53.69 mmol) was added, the flask then was sealed and vacuum purged three 
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times, refilling with argon.  Tetrahyrdofuran (89 mL) was added and the solution was stirred 5 
minutes at room temperature before being cooled to -78oC for 10 minutes.  6-bromo-3-(2-
nitrovinyl)-1H-indole 1.10 (2.39 g, 8.94 mmol) was dissolved in 89 mL THF and added dropwise 
via syringe to the stirred solution.  The reaction was allowed to warm to room temperature 
overnight.  The reaction was monitored by thin layer chromatography over 24 hours.  After 24 
hours, the flask was placed in an ice bath and cooled for 5 minutes before the careful addition of 2 
mL water, followed by 2 mL 15% aq. NaOH, followed by 6 mL water.  The flask was stirred for 
30 minutes and a small amount of MgSO4 was added.  The mixture was then filtered through a 
glass frit, washing the formed solid with dichloromethane.  The resulting brown solution was then 
concentrated to afford a crude brown oil.  The product was purified on silica (80:18:2 
CHCl3:MeOH:NH4OH), yielded 1.63 g  (76%) 1.8 as a brown solid.  1H NMR (600.1 MHz, 
CD3OD) δ (ppm): 7.56 (d, J = 1.65 Hz, 1 H), 7.51 (d, J = 8.51 Hz, 1H), 7.21 (s, 1H), 7.18 (d, J = 
7.51 Hz, 1H) 3.24 (t, J = 7.63 Hz, 2H) 3.12 (t, J = 7.63 Hz, 2H); 13C NMR (150 MHz, CD3OD) δ 
(ppm): 137.5, 126.2, 122.9, 121.2, 119.2, 114.3, 113.6, 112.4, 41.5, 27.8;  HRMS (TOF, ES+)  
C10H12N2Br [M+H]+ m/z  239.0184, measured 239.0182. 
 
N-(2-(6-bromo-1H-indol-3-yl)ethyl)-4-(1,3-dioxoisoindolin-2-yl)butanamide (1.24). 
6-Bromotryptamine (1.8) (1.0 g, 4.18 mmol), 4-(1,3-dioxoisoindolin-2-yl)butanoic acid (1.23) 
(1.17 g, 5.01 mmol) EDC (1.60 g, 8.36 mmol), and HOBT (1.12 g, 8.36 mmol) were dissolved in 
30 mL 9:1 DCM:DIEA solution.  The mixture was stirred 12 hours.  Analysis by LCMS showed 
product conversion.  The contents of the flask were transferred to a 500 mL separatory funnel, 
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150 mL water was added and the solution was extracted 3 times with DCM.  The combined 
organic phase was dried over MgSO4 and concentrated under reduced pressure.  The product was 
purified on silica (DCM  2% MeOH in DCM) and isolated 1.24 as a yellow solid 1.61 g (85%).  
1H NMR (600.1 MHz, CDCl3) δ (ppm): 8.09 (s, 1H), 7.78 (dq, J = 8.45, 57.8 Hz, 4H), 7.52 (d, J 
= 1.65 Hz, 1H), 7.48 (d, J = 8.45 Hz, 1H), 7.22 (dd, J = 1.65, 8.45 Hz, 1H) 7.07 (d, J = 2.25 Hz, 
1H), 5.93 (s, 1H), 3.69 (t, J = 6.36 Hz, 2H), 3.59 (q, J = 6.79, 6.10 Hz, 2H), 2.97 (t, J = 6.91 Hz, 
2H), 2.17 (t, J = 7.13 Hz, 2H), 2.01 (p, J = 6.91 Hz, 2H), 1.58 (s, 1H); 13C NMR (150 MHz, 
CD3OD) δ (ppm): 171.7, 168.5, 137.0, 134.0, 131.9, 126.3, 123.2, 122.7, 122.5, 120.0, 115.7, 114.0, 
113.3, 39.6, 37.1, 33.8, 25.1, 24.8; HRMS (TOF, ES+)  C22H21N3O3Br [M+H]+ m/z  454.0766, 
measured 454.0764. 
 
2-(3-(7-bromo-4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl)propyl)isoindoline-1,3-dione (1.28). 
N-(2-(6-bromo-1H-indol-3-yl)ethyl)-4-(1,3-dioxoisoindolin-2-yl)butanamide (1.24) (1.23 g, 2.71 
mmol) was placed in a 250 round bottom flask.  Acetonitrile (25 mL) was added, followed by 
POCl3 (2.08 g, 1.67 mmol).  The flask was then brought to reflux for 1 hour.  Starting material 
loss and product conversion were monitored by TLC and LCMS.  After 1 hour, the flask was 
removed from the heating bath and the excess POCl3 was evaporated under reduced pressure.  
The flask contents were then transferred to a 500 mL separatory funnel, washing with DCM, 100 
mL water was added and the solution was extracted three times with DCM.  The combined 
organic phased was concentrated and purified on silica (30:1 CHCl3:MeOH) to afford 1.043 g 
(88%) 1.28.  1H NMR (600.1 MHz, CD3OD) δ (ppm): 7.73 (s, 4H), 7.66 (d, J = 1.49 Hz, 1H), 7.54 
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(d, J = 8.74 Hz, 1H), 7.27 (dd, J = 1.51 Hz, 8.74, 1H), 3.94 (t, J = 8.97 Hz, 2H), 3.83 (t, J = 6.49 
Hz, 2H), 3.15 (t, J = 9.08 Hz, 2H), 3.12 (t, J = 8.93 Hz, 1H), 2.28 (p, J = 7.03 Hz, 2H); 13C NMR 
(150 MHz, CD3OD) δ (ppm): 169.5, 168.2, 141.8, 134.0, 131.6, 125.8, 135.1, 125.0, 122.9, 
122.85, 122.81, 122.6, 115.5, 42.2, 36.5, 29.9, 25.5, 18.2; HRMS (TOF, ES+)  C22H19N3O2Br 
[M+H]+ m/z  436.0661, measured 436.0663. 
 
(R)-2-(3-(7-bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)propyl)isoindoline-1,3-
dione (1.19). 
A 100 mL round bottom flask was charged with 1.28 (893 mg, 2.046 mmol) and 1.21 (118.4 mg, 
0.204 mmol) and DMF (7.8 mL) was added.  The flask was cooled to 0oC and a solution of 
premixed 5:2 formic acid:triethylamine (1.75 mL) was added.  The flask was sealed, stirred, and 
allowed to warm overnight.  Reaction progress was monitored by LCMS. After 12 hours, the 
flask contents were transferred to a 250 mL separatory funnel, washing with DCM.  Water (50 
mL) was added and the solution was extracted 3 times with DCM.  The combined organic phase 
was dried over MgSO4 and concentrated.  The product was purified on silica (30:1 
CHCl3:MeOH), yielded 717.4 mg 1.19 as a golden-brown solid. [α]D23 35.5o (c = 1.0, MeOH);  1H 
NMR (600.1 MHz, CD3OD) δ (ppm): 7.85 (m, 4H), 7.49 (d, J = 1.56 Hz, 1H), 7.38 (d, J = 8.50 
Hz, 1H), 7.17 (dd, J =1.56, 8.50 Hz, 1H), 4.75 (m, 1H), 3.84 (t, J = 6.51 Hz, 2H), 3.73 (m, 1H) 
3.44 (m, 1H), 3.04 (m, 2H), 2.30 (m, 1H), 1.96 (m, 3H); 13C NMR (150 MHz, CD3OD) δ (ppm): 
168.4, 137.5, 134.0, 131.8, 129.3, 124.8, 122.7, 122.3, 119.1, 115.4, 113.7, 106.2, 52.8, 41.3, 
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36.6, 29.0, 23.9, 17.8; HRMS (TOF, ES+)  C22H21N3O2Br [M+H]+ m/z  438.0817, measured 
438.0814.    
 
(R)-3-(7-bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)propan-1-amine (1.29). 
A 100 mL round bottom flask was charged with 1.19 (514 mg, 1.17 mmol).  EtOH was added (10 
mL), followed by hydrazine hydrate (368 uL, 11.72 mmol).  The flask was brought to reflux for 
45 minutes, monitoring by LCMS.  After 45 minutes, the flask was cooled and the contents were 
concentrated to remove ethanol.  The product was purified on silica (80:18:2 
CHCl3:MeOH:NH4OH), yielded  317.3 mg (88%) 1.29 as a brown solid. [α]D23 28.5o (c = 2.0, 
MeOH); 1H NMR (600.1 MHz, CD3OD) δ (ppm): 7.56 (d, J = 1.58 Hz, 1H), 7.39 (d, J = 8.43 Hz, 
1H), 7.17 (dd, J = 1.58, 8.43 Hz, 1H), 4.77 (q, J = 4.41 Hz, 1H), 3.75 (m, 1H), 3.49 (m, 1H), 3.07 
(m, 4H), 2.34 (m, 1H), 2.11 (m, 1H), 1.97 (m, 2H); 13C NMR (150 MHz, CD3OD) δ (ppm): 
161.1, 160.9, 137.6, 129.1, 124.9, 122.4, 119.2, 115.4, 113.9, 106.5, 52.5, 41.2, 38.7, 28.6, 22.8, 
17.8; HRMS (TOF, ES+)  C14H19N3Br [M+H]+ m/z  308.0862, measured 308.0759. 
 
(+)-7-Bromotrypargine (1.7). 
A 50 mL round bottom flask was charged with 1.29 (231 mg, 0.749 mmol) and DCM (3 mL).  
N,N’-Bis(Boc)-1H-pyrazole-1-carboxamidine (255.8 mg, 0.824 mmol) and triethylamine (156 
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uL, 1.12 mmol) were then added.  The flask was stirred 3 hours and monitored by TLC and 
LCMS.  After three hours, 5 mL trifluoroacetic acid were added and the reaction was stirred 4 
hours.  Reaction progress was monitored by LCMS.  After 4 hours, the reaction was concentrated 
and the product was purified by revere phase high performance liquid chromatography using 
acetonitrile and 0.1% TFA/water (gradient: 10:90 to 90:10), yielded 225 mg (86% over two steps) 
1.7 as a glassy yellow solid. [α]D23 40.0o (c = 1.0, MeOH);  1H NMR (600.1 MHz, d6-DMSO) δ 
(ppm):  11.3 (s, 1H), 9.49 (s, 1H), 9.00 (s, 1H), 7.73 ( br s, 1H), 7.56 (d, J = 1.68 Hz, 1H), 7.46 
(d, J = 8.50 Hz, 1H), 7.20 (br s, 2H), 7.18 (br s, 2H), 7.18 (dd, J = 1.68, 8.50 Hz, 1H), 4.69 (s, 
1H), 3.58 (m, 1H), 3.34 (m, 1H), 3.18 (m, 2H), 2.93 (t, J = 5.5 Hz, 2H), 2.11 (m, 1H), 1.90 (m, 
1H), 1.69 (m, 1H); 13C NMR (150 MHz, d6-DMSO) δ (ppm): 157.2, 137.5, 131.4, 125.2, 122.4, 
120.3, 118.5, 114.9, 114.3, 106.6, 52.2, 40.9, 40.7, 28.9, 24.7, 18.4; HRMS (TOF, ES+)  
C15H21N5Br [M+H]+ m/z  350.0980, measured 350.0982. 
 
(R)-2-(3-(7-bromo-2-propyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-
yl)propyl)isoindoline-1,3-dione (1.30).  
A 50 mL round bottom flask was charged with 1.19 (173 mg, 0.395 mmol), propionaldehyde 
(45.8 mg, 0.789 mmol), and dichloroethane (3 mL).  The solution was stirred 30 minutes before 
the addition of NaBH(OAc)3  (125.4 mg, 0.592 mmol).  The mixture was stirred 2 hours, 
monitoring by TLC and LCMS.  After two hours, the reaction was quenched with the addition of 
5 mL water, 2 mL 1N HCl.  The reaction mixture was then transferred to a separatory funnel and 
extracted 3 times with DCM.  The combined organic phase was dried over MgSO4 before being 
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concentrated under reduced pressure.  The brown solid was then purified on silica (1:31:2 
EtOAc:hexanes), yielded 132 mg (70%) 1.30 as a golden brown solid. 1H NMR (500.1 MHz, 
CD3OD) δ (ppm):  7.79 (m, 4H), 7.50 (s, 1H), 7.38 (d, J = 8.25 Hz, 1H), 7.16 (dd, J = 1.47, 8.44 
Hz, 1H), 4.71 (m, 1H), 3.78 (t, J = 6.44 Hz, 3H) 3.64 (m, 1H), 3.20 (m, 2H), 3.08 (m, 2H), 2.18 
(m, 2H), 1.96 (m, 2H), 1.86 (m, 2H), 0.99 (m, 3H); 13C NMR (125 MHz, CD3OD) δ (ppm): 
168.4, 137.6, 133.9, 131.7, 127.9, 124.5, 133.6, 122.4, 119.2, 115.6, 115.5, 113.8, 59.5, 54.0, 
45.0, 36.5, 30.1, 24.3, 17.8, 15.3, 9.6; HRMS (TOF, ES+)  C25H27N3O2Br [M+H]+ m/z  480.1287, 
measured 480.1287. 
 
(R)-3-(7-bromo-2-propyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)propan-1-amine 
(1.31). 
A 100 mL round bottom flask was charged with 1.30 (120 mg, 0.249 mmol).  EtOH (2 mL) was 
added, followed by hydrazine hydrate (78.4 uL, 2.49 mmol).  The flask was brought to reflux for 
45 minutes, monitoring by LCMS.  After 45 minutes, the flask was cooled and the contents were 
concentrated to remove ethanol.  The product was purified on silica (80:18:2 
CHCl3:MeOH:NH4OH), yielded 1.31 76.7 mg (88%) as a brown solid. 1H NMR (500.1 MHz, 
CD3OD) δ (ppm): 7.42 (d, J = 1.50 Hz, 1H), 7.30 (d, J = 8.49 Hz, 1H), 7.07 (dd, J = 1.50, 8.49 
Hz, 1H), 4.71 (m, 1H), 3.72 (t, J = 5.5 Hz, 1H), 2.87 (m, 1H), 2.77 (m, 2H), 2.60 (m, 2H), 1.95 
(m, 2H), 1.63 (m, 3H), 1.29 (m, 2H), 0.95 (m, 3H); 13C NMR (125 MHz, CD3OD) δ (ppm): 
137.1, 135.3, 125.8, 121.2, 118.4, 113.6, 113.1, 107.0, 57.2, 54.7, 45.00, 40.37, 30.3, 26.9, 20.1, 
17.7, 10.7; HRMS (TOF, ES+)  C17H25N3Br [M+H]+ m/z  350.1232, measured 350.1235. 
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(R)-N-(3-(7-bromo-2-propyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)propyl)-3,5-
dimethoxybenzamide (1.32). 
A 10 mL round bottom flask was charged with 1.31 (20 mg, 0.057 mmol), 3,5-
dimethoxybenzoylchloride (11.45 mg, 0.057 mmol), triethylamine (20 uL) and  DCM (2 mL).  
The flask was stirred for 3 hours, monitoring by LCMS.  After 3 hours, water (3 mL) and DCM 
(2 mL) were added and the biphasic solution was stirred vigorously before being passed through 
an Isolute phase separator.  The resulting organic layer was then concentrated and purified by 
revere phase high performance liquid chromatography using acetonitrile and 0.1% TFA/water 
(gradient: 10:90 to 90:10). Isolated 26 mg (86%) 1.32 as a brown solid.  1H NMR (500.1 MHz, 
CD3OD) δ (ppm): 7.54 (d, J = 1.24 Hz, 1H), 7.40 (d, J = 8.50 Hz, 1H), 7.17 (dd, J = 1.24, 8.50 
Hz, 1H), 6.97 (d, J = 1.65 Hz, 2H), 6.64 (t, J = 2.15 Hz, 1H), 4.72 (m, 1H), 3.80 (s, 6H), 3.65 (m, 
1H), 3.48 (m, 2H), 3.20 (t, J = 8.01 Hz, 2H), 3.08 (m, 2H), 2.18 (m, 2H), 1.88 (p, J = 7.24, 4H), 
1.00 (m, 3H); 13C NMR (125 MHz, CD3OD) δ (ppm): 168.7, 160.9, 137.7, 135.8, 128.2, 124.5, 
122.4, 119.2, 115.5, 113.9, 104.7, 103.0, 59.7, 54.5, 54.0, 45.0, 38.9, 38.6, 30.0, 25.4, 17.8, 15.4, 
9.6; HRMS (TOF, ES+)  C26H33N3O3Br [M+H]+ m/z  514.1705, measured 514.1708. 
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(R)-N-(3-(7-bromo-2-propyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)propyl)-1-
phenylmethanesulfonamide (1.33). 
A 10 mL round bottom flask was charged with 1.31 (20 mg, 0.057 mmol), 
benzylmethanesulfonylchloride (10.86 mg, 0.057 mmol), triethylamine (20 uL) and DCM (2 mL).  
The flask was stirred for 3 hours, monitoring by LCMS.  After 3 hours, water (3 mL) and DCM 
(2 mL) were added and the biphasic solution was stirred vigorously before being passed through 
an Isolute phase separator.  The resulting organic layer was then concentrated and purified by 
revere phase high performance liquid chromatography using acetonitrile and 0.1% TFA/water 
(gradient: 10:90 to 90:10).  Isolated 25 mg (85%) 1.33 as a brown solid.  1H NMR (500.1 MHz, 
CD3OD) δ (ppm): 7.54 (d, J = 1.45 Hz, 1H), 7.37 (m, 6H), 7.18 (dd, J = 1.45 Hz, 8.40, 1H), 4.65 
(m, 1H), 4.30 (m, 2H), 3.76 (m, 1H), 3.63 (m, 1H), 3.17 (t, J = 7.84 Hz, 2H), 3.07 (m, 2H), 3.03 
(t, J = 6.19 Hz, 2H), 2.15 (m, 2H), 1.86 (m, 2H), 1.74 (m, 2H), 0.99 (m, 3H); 13C NMR (125 
MHz, CD3OD) δ (ppm): 161.2, 160.9, 137.6, 130.4, 129.7, 128.1, 128.0, 124.5, 122.4, 119.3, 
117.7, 115.5, 113.9, 104.8, 59.5, 57.6, 54.0, 45.2, 42.1, 29.7, 26.2, 17.7, 15.5, 9.7; HRMS (TOF, 
ES+)  C24H31N3O2Br [M+H]+ m/z  504.1320, measured 504.1320. 
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(R)-1-(3-(7-bromo-2-propyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)propyl)guanidine 
(1.34). 
A 10 mL round bottom flask was charged with 1.31 (20 mg, 0.057 mmol), N,N’-Bis(Boc)-1H-
pyrazole-1-carboxamidine (17.69 mg, 0.057 mmol), triethylamine (20 uL) and  DCM (2 mL).  
The flask was stirred for 3 hours, monitoring by LCMS.  After 3 hours, water (3 mL) and DCM 
(2 mL) were added and the biphasic solution was stirred vigorously before being passed through 
an Isolute phase separator.  The resulting organic layer was then concentrated and purified by 
revere phase high performance liquid chromatography using acetonitrile and 0.1% TFA/water 
(gradient: 10:90 to 90:10) to afford 20 mg (89%) 1.34 as a glassy brown solid.  1H NMR (600.1 
MHz, CD3OD) δ (ppm): 7.55 (d, J = 1.50 Hz, 1H), 7.43 (d, J = 8.47 Hz, 1H), 7.20 (dd, J = 1.50, 
8.47 Hz, 1H), 4.70 (m, 1H), 3.81 (m, 1H), 3.66 (m, 1H), 3.26 (dt, J = 2.33, 7.12 Hz, 2H), 3.23 (m, 
2H), 3.11 (m, 2H), 2.22 (m, 2H), 1.87 (m, 4H), 1.04 (m, 3H); 13C NMR (150 MHz, CD3OD) δ 
(ppm): 157.2, 137.7, 128.1, 124.6, 122.5, 119.3, 115.7, 113.9, 104.9, 59.6, 54.1, 45.1, 38.9, 34.4, 
30.0, 24.8, 19.6, 18.2, 17.8, 15.4, 9.70;  HRMS (TOF, ES+) C18H27N5Br [M+H]+ m/z  504.1320, 
measured 504.1320. 
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Table 1.8.1: NMR Shift Correlation Tables for 1.7.   
Natural (+)-7-Bromotrypargine Synthetic (+)-7-Bromotrypargine 
1H δ ppm (DMSO) Integration J 1H δ ppm (DMSO) Integration J 
1.69 m, 2H 1.69 m, 2H 
1.92 m, 1H 1.90 m, 1H 
2.13 m, 1H 2.11 m, 1H 
2.93 m, 2H 2.93 t, 2H 5.5 
3.19 m, 2H 3.18 m, 2H 
3.34 m, 1H 3.34 m, 1H 
3.57 dt, 1H 12.0, 4.8 3.58 m, 1H 
4.69 br m, 1H 4.69 br s, 1H 
7.1 br s, 2H 7.18 br s, 2H 
7.1 br s, 2H 7.22 br s, 2H 
7.16 dd, 1H 1.8, 8.4 7.18 dd, 1H 1.68, 8.5 
7.44 d, 1H 8.4 7.45 d, 1H 8.5 
7.54 d, 1H 1.8 7.55 d, 1H 1.68 
7.81 t, 1H 5.4 7.73 s, 1H 
9.09 br s, 1H 8.98 br s, 1H 
9.62 br s, 1H 9.48 br s, 1H 
11.34 s, 1H 11.32 s, 1H 
 
Natural (+)-7-
Bromotrypargine
Synthetic (+)-7-
Bromotrypargine
13C δ ppm 
(DMSO)   
13C δ ppm 
(DMSO)   
18.6 18.4 
23.9 24.7 
28.0 28.9 
40.3 40.7 
40.3 40.9 
52.1 52.2 
106.5 106.6 
114.0 114.9 
114.7 116.5 
119.1 120.3 
122.2 122.4 
125.0 125.2 
131.0 131.4 
137.3 137.5 
157.2 157.2 
 
 
  
C
(+
 
 
 
hiral SFC Tra
)-1.19 
ces:  
28 
 
  
(±
 
 
 
 
)-1.19  
29 
 
 30 
 
Cell Culture and HCT116 Viability Assay: 
HCT116 cells were grown at 37°C in a humidified incubator with 5% CO2 in DMEM + 10% 
FBS.  Cells were plated in growth medium at 8000 cells per well (100 µl) in 96 well plates and 
allowed to attach for 24 hrs.  No cells were plated in the first column.  Fresh DMEM + 10% FBS 
+ penicillin/streptomycin (100 µl) containing the final concentrations of DMSO or 1.7 or 1.29 or 
podophyllotoxin dilutions in DMSO (DMSO concentration maintained at 0.1%) was replaced in 
each well.  After 48 hours of cell growth with respective treatments, WST-1 Cell Proliferation 
Reagent (Roche, 11644807001) was added (10 µl) to each well for 45-60 min at 37°C.  The plates 
were read (Molecular Devices) at 450 nm for the formazan product and at 690 nm as a reference. 
Background absorbance (medium only plus WST-1, first column) was averaged and subtracted 
from all values.  Six replicates were used in the calculations per treatment concentration in 
duplicate experiments.  Data was plotted as a percentage of metabolism of WST-1 in the DMSO-
treated cells.  A colorectal adenocarcinoma cell line, SW620, and a squamous cell lung carcinoma 
cell line, H520, were obtained from the American Type Culture Collection (Manassas, VA) and 
maintained in a humidified atmosphere of 5% CO2 in air at 37 °C.  The cells were routinely 
cultured in RPMI 1640 supplemented with 10% fetal bovine serum (Atlanta Biologicals, GA) and 
100 μg/mL penicillin-streptomycin.   
Proliferation Analysis:   
SW620 and H520 cells (2.5 x 104/100 μL) were seeded in 96-well microtiter plates prior to 
treatment. Cells were treated with 10 μM concentration of synthesized compound in triplicate for 
48 hours in RPMI 1640 supplemented medium and 100 μg/mL penicillin-streptomycin.  The 
CycLex® Cellular BrdU ELISA Kit from MBL International (Woburn, MA) was used to measure 
proliferation.  The RPMI media was removed and replaced with 100 μL of 1x BrdU label mix in 
RPMI media for 2 hours at 37 °C in 5% CO2 in the air. The BrdU label mix was removed and 200 
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μL of the Fix/Denature solution was added and incubated for 30 minutes at room temperature.  
The plate was drained, incubated with 50 μL of primary antibody for 1 hour at room temperature, 
rinsed with wash buffer, and incubated with 50 μL of secondary antibody.  The wells were rinsed 
with wash buffer followed by a single rinse with PBS and drained.  Fifty microliters of substrate 
solution was added and incubated for 6 minutes followed immediately by 50 μL of Stop solution.  
The change in proliferation was quantified by measuring the absorbance of the dye solution at 
450 nm on a microtiter plate reader. 
Radioligand Binding and Functional assays.  All biological assays were conducted at Ricerca 
Pharma according to published protocols. 
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Figure 2.1.2: Structures of phidianidines A(2.1) and B(2.2). 
Compounds 2.1 and 2.2 represent the first natural products identified to contain a 1,2,4-
oxadiazole heterocycle (Figure 2.1.2)29.  These two structures share similar topology with 1.7 and 
conform to the H3 pharmacophore model11; therefore, we initiated a synthesis campaign towards 
both 2.1 and 2.2 to provide sufficient material for pharmacological study.   
2.2 Retrosynthetic Analysis of Phidianidines A & B 
Our retrosynthesis followed the biogenetic pathway proposed by Gavagnin, Guo and co-
workers29.  By disconnecting across the oxadiazole ring, the molecule can be separated into 
respective “western” and “eastern” sections, enabling a convergent synthesis.  The core of 2.1 and 
2.2 could be joined by a key coupling between indole acetic acids 2.3 and 2.4 and an 
appropriately oxidized, alkyl bis-guanidine 2.5 (Figure 2.2.1), the latter of which being derived 
from 1,5-diaminopentane 2.6.   
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Figure 2.2.1: Retrosynthetic analysis of phidianidines A and B. 
2.3 Eastern Section Synthesis 
Synthesis of the eastern section began with a mono-carboxybenzyl (CBz) protection of 
2.6 to furnish amine 2.7.  This protecting group was selected in order to add a chromophore to the 
structure in order to ease detection by LCMS and TLC.  Cyanation with cyanogen bromide 
proceeded smoothly, yielding amino nitrile 2.8.  The eastern section was completed with 
hydroxyguanidine formation using hydroxylamine hydrochloride under basic conditions at room 
temperature.   
 
Scheme 2.3.1: First synthesis of eastern section. 
 35 
 
However, when we attempted to deprotect the carboxybenzyl group, we found the 
functionality to be extremely intractable toward all attempted hydrogenation conditions.  We 
modified reaction temperature, solvent, and palladium source, however, no deprotected product 
was observed.  As a result, we returned to the eastern synthesis and replaced the carboxybenzyl 
group with a tert-butyl carbamate (Boc) group.     
 
Scheme 2.3.2: Second synthesis of eastern section. 
2.4 Western Section Synthesis 
Synthesis of the western section required significantly more experimentation due to the 
fact that indole-3-acetic acids remain surprisingly difficult to assemble, despite their relative 
structural simplicity.  Indole-3-acetic acid is an essential plant auxin and has been the subject of 
significant investigation regarding its plant growth regulating properties30.  Commercially, indole-
3-acetic acid is generated at high temperatures and pressures in a stainless steel rocking 
autoclave; indole and glycolic acid are heated with aqueous potassium hydroxide to a temperature 
of 250o C for 18 hours31.  Subsequent acidification of the potassium salt yields the desired 
material in reportedly high yields.  As a result, the undecorated indole-3-acetic acid required for 
the synthesis of 2.2 is commercially available; however 6-bromoindole-3-acetic acid (2.3) is not, 
making its synthesis an essential intermediate en route to 2.1.  Due to a lack of access to a 
stainless steel rocking autoclave, we were prompted to explore alternate routes toward this 
intermediate. 
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Scheme 2.4.1: Industrial scale synthesis route toward indole-3-acetic acid. 
2.4.1 Proposed Routes Toward 6-Bromoindole-3-Acetic Acid 
Alternate published routes toward indole-3-acetic acid include preparation by Fischer 
indole synthesis, hydrolysis of indoleacetonitrile, reaction of indole with ethyl diazoacetate 
followed by hydrolysis, and ultraviolet irradiation of tryptophan31.  Of these routes, Fisher indole 
synthesis was the least optimal.  As Scheme 2.4.1.1 shows, reaction of 3-bromophenylhyrdrazine 
2.15 with 3-oxopropanoic acid 2.16, or a protected congener thereof, would yield two inseparable 
regioisomers of brominated indole-3-acetic acid.   
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Scheme 2.4.1.1: Fisher indole synthesis of indole-3-acetic acid. 
As opening the indole ring would invite issues of regioisomerism, we opted to begin our 
synthesis of 2.3 with the brominated indole ring intact.  Returning to the previously published 
routes toward 2.3, the synthesis of 6-bromoindole-3-acetonitrile features the same problems as 
2.3, and ultraviolet irradiation of tryptophan would furnish des-bromo material.  Thus, our focus 
centered on routes toward this intermediate that would involve alkylation or acylation of 6-
bromoindole at the C3-position.    
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2.4.2 Acylation Route  
For our first route toward 2.3, we envisioned a Friedel-Crafts acylation of the indole ring, 
full reduction to the terminal alcohol and subsequent reoxidation to the carboxylic acid oxidation 
state.  Friedel-Crafts acylation of 6-bromoindole at the C3-position with oxalyl chloride in diethyl 
ether, followed by methanol quench produced the corresponding keto-ester.  Exhaustive reduction 
of the keto-ester with refluxing lithium aluminum hydride furnished the desired tryptanol (2.23) 
in good yield over three steps32.  From the alcohol, we attempted a number of different oxidation 
reactions: Swern, Ley33,34, IBX35, Oxone36, Dess-Martin periodinane37, and chromium reagents 
including pyridinium chlorochromate and pyridinuim dichromate38.  All of these attempted 
reactions resulted in either unaffected starting material or total decomposition.   
 
Scheme 2.4.2.1: Attempted acylation route toward 2.3 
2.4.3 Olefin Cleavage Route 
Because oxidation upward from the alcohol oxidation state primarily lead to 
decomposition of starting material, we decided that our next route should convert an alternate 
functionality directly to the aldehyde or carboxylic acid oxidation states.  To that end, we 
considered the cleavage of a terminal olefin.  Kimura and coworkers recently reported on a 
technique to selectively allylate the C-3 position of indoles with allyl alcohol, triethylborane and 
a palladium(0) source39.  We employed palladium tetrakis triphenylphosphine and smoothly 
allylated 2.21, furnishing allyl indole 2.24A.  However, we again met with decomposition when 
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we attempted to cleave the terminal olefin.  Ozonolysis, ruthenium trichloride/sodium periodate40, 
and osmium tetroxide41 were all employed under various reaction parameters, however, in each 
case, the starting material was found to have decomposed during the course of the reaction.  
Because the indole ring is electron excessive, we considered the possibility that these harsh 
reagents might be opening the ring across the C-2 to C-3 bond.  In order to test this hypothesis, 
we introduced an electron withdrawing protecting group in the form of a tosylate on the indole 
nitrogen of 2.24 (2.23B)42 and attempted the range of different cleavage conditions again. 
Unfortunately, this modification did not prompt these reactions to yield the desired product.   
 
Scheme 2.4.3.1: Attempted olefin cleavage route 
2.4.4 Direct Alkylation Route 
After encountering the series of issues surrounding oxidation state manipulation and 
functional group interconversion, we decided to move forward by attempting to install the desired 
functionality in its correct oxidation state.  Yadav and coworkers recently published a procedure 
for a copper triflate or indium tribromide mediated direct alkylation of indoles and pyrroles with 
ethyl diazoacetate43.  When we attempted these reactions, indium tribromide failed to catalyze the 
reaction entirely, however, copper(II) triflate successfully catalyzed the alkylation of the indole 
ring with ethyl diazoacetate.  Frustratingly, despite variations in stoichiometric ratios of starting 
materials, catalyst loading, solvent, reaction temperature and reaction concentration, the 
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alkylation produced an inseparable mixture of mono-(2.26) and bis-(2.27) alkylated products at 
the C-3 and C-4 positions of the indole ring (Scheme 2.4.4.1).   
 
Scheme 2.4.4.1: Attempted alkylation of 2.21 with copper(II) triflate and ethyl diazoacetate. 
2.4.5 Chemoselective Reduction Route 
Because the Friedel-Crafts C-3 acylation reaction proceeded smoothly and produced the 
desired oxidation state at the terminal carbon when quenched with an oxygen source such as 
methanol, we decided to return to this previous route.  Rather than performing a total reduction, 
we decided to focus on a chemoselective reduction of the ketone over the terminal ester/acid 
functionality.  Examples of such chemoselective reductions include a dithiane condensation 
followed by hydrogenation and the Wolff-Kishner reduction. 
2.4.5.1 Dithiane Condensation/Reduction Route 
Our first attempted chemoselective reduction began with an acid-mediated dithiane 
condensation of previously synthesized keto-ester 2.22 with dithioethane, forming dithiane 2.23.  
With this material in hand, we attempted a range of different Raney-nickel hydrogenation 
conditions44 on the bench top and in the H-cube reactor but were unsuccessful in desulfurizing 
2.28 (Scheme 2.4.5.1), as starting material was retrieved from the reaction in each case.  
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Scheme 2.4.5.1: Attempted dithiane condensation/reduction route. 
2.4.5.2 Wolff-Kishner Reduction Route 
As an alternative to the unsuccessful dithiane reduction, we attempted standard Wolff-
Kishner reduction of 2.22, but quickly encountered literature precedent showing that, while α-
keto-esters fail, α-keto-acids can be efficiently reduced by modifying base from potassium 
hydroxide to sodium methoxide and solvent from ethylene glycol to 2-ethoxyethanol45.  By 
affecting these modifications and heating in the microwave reactor, we were able to successfully 
synthesize 2.3 in approximately 90% yield over three steps.   
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Scheme 2.4.5.2: Synthesis of 6-bromoindole-3-acetic acid45. 
2.5 Coupling, Cyclization and Final Steps 
With both the western and eastern sections in hand, we continued forward with the 
synthesis of 2.1 and 2.2.  Using commercially available 2.4, we experimented with conditions to 
couple the two sections together, dehydrate/cyclize the oxadiazole ring, and remove the Boc 
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protecting group in one pot.  Our initial conditions (Scheme 2.5.1) involved a HATU mediated 
coupling of the two sections in DMF for roughly 30 minutes, heating the reaction to 100o C for 1 
hour in order to close the oxadiazole ring, and acidic cleavage of the Boc group.   
 
Scheme 2.5.1: Initial conditions for coupling, cyclization, and Boc group removal.  
While we were gratified to find that the reaction proceeded, the product yield of 25% was 
unacceptably low.  In an effort to increase the yield, we performed a solvent screen and found 
that by substituting a co-solvent system of DCM/DCE for DMF, the product yield increased to 
45% over two steps from 2.4 and 2.12.  Contrastingly, when we employed 2.3 under the same 
reaction, we found the yield to be significantly higher (74% over two steps, Scheme 2.5.2).  This 
difference in yield can be attributed to the relatively poor solubility of 2.4 in DCM, whereas 2.3 is 
readily soluble in the same solvent.  Despite the solubility issue, the 45% yield was viewed as 
acceptable enough to complete the synthesis.   
 
Scheme 2.5.2: Optimized conditions for coupling, cyclization, and Boc group removal. 
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The final steps of the synthesis involved guanidation of the primary amine with N,N’-
Bis(Boc)-1H-pyrazole-1-carboxamidine and trifluoroacetic acid mediated cleavage of the bis-Boc 
protecting groups (Scheme 2.5.3) to yield the TFA salts of 2.1 and 2.2 in six steps and 40% and 
21% overall yields, respectively. 
 
Scheme 2.5.3: Final steps in the synthesis of 2.1 and 2.2 
As we were writing our manuscript, a Letter46 appeared from Snider describing the 
synthesis of 2.1 and 2.2, starting from a 1,5-diazidopentane and a similar approach, requiring 8 
steps and 19% overall yields.  In their work, 2.1 and 2.2 were evaluated in the National Cancer 
Institute 60 cell line panel and showed only 5-30% inhibition of cell growth46.  Our synthetic 2.1 
and 2.2 were in complete agreement with natural 2.1 and 2.229, as well as the data reported by 
Snider46; moreover, the expedited route and high yields in our synthesis was amenable to 
unnatural analog development. 
2.6 Cytotoxicity Screening 
As 2.1 and 2.2 display a range of cytotoxicity across tumor and non-transformed cell 
lines29,46, we first evaluated the cytotoxicity of 2.1 and 2.2  in Human Embryonic Kidney 
(HEK293) cells after both 24 and 48 hours in a WST-1 cell proliferation assay47.  At 
concentrations of 10 M, neither 2.1 nor 2.2 displayed any toxicity, relative to DMSO control at 
24 and 48 hour time points in HEK293 cells (Figure 2.6.1).  Thus, we advanced 2.1 and 2.2 into 
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phidianidine B (2.2) showed a similar profile.  The OR is a Class A GPCR that has been shown 
to be the OR subtype responsible for the analgesia of clinical opioids49,50,51,52, and has been 
implicated in a number of other CNS pathologies54.  In order to discern preliminary SAR, we also 
evaluated the amine precursor 2.32 en route to 2.1 in the same panel assay.   In this instance, 2.32 
not only displayed potent DAT and NET activity (98% and 86% inhibition at 10 M, 
respectively), but also selective OR activity (88% at 10 M for OR, 2% at 10 M for - and 
OR), suggesting the guanidine moiety of 2.1 is not essential for the pharmacological profiles. 
Table 2.7.1: Pharmacological profiles of 2.1, 2.2, and precursor amine 2.32. 
 
We then followed up the single point radioligand binding assays26, with full concentration 
response curves (CRCs) for 2.1, 2.2 and 2.32, and determined quantitative Ki values and IC50 
values for DAT inhibition (Table 2.7.2)53.  In parallel, we ran the standard GTPS functional 
assay, measuring an increase in bound [35S]GTPγS relative to DAMGO response54, to determine 
if 2.1, 2.2 and 2.32 were functional agonists of the -opioid receptor.   We found that 2.1 and 2.2 
were potent ligands for both DAT (Ki values of 310 nM and 680 nM, respectively) and OR (Ki 
values of 230 nM and 340 nM, respectively).  The amine precursor was weaker, but still 
displayed submicromolar Ki values for both DAT and OR (Ki values of 690 nM and 800 nM, 
respectively).  All three compounds also displayed potent inhibition of DAT, with IC50 values 
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ranging from 390 nM to 870 nM.  In the GTPS functional assay,50,53 2.32 was inactive, but both 
2.1 and 2.2  displayed weak, partial agonism (12-17% increase in bound [35S]GTPS at 10 M, 
relative to DAMGO response) of the -opioid receptor.  While these represent very weak agonist 
responses, we were excited to identify a fundamentally new chemotype with high selectivity for 
binding to the -opioid receptor, and an attractive lead for chemical optimization. 
Table 2.7.2: Quantitative pharmacological profile of 2.1, 2.2, and amine precursor 2.32. 
 
2.8 Unnatural Analog Development 
In order to optimize and develop SAR around the selective OR activity, we required 
reliable, rapid chemistry to prepare unnatural analogs of 2.1 and 2.2 (Figure 2.8.1). While the 
phidianidine scaffold features several functional group “handles” that enable access to different 
chemical modifications, the data concerning 2.32 suggests that the guanidine moiety is not 
required for OR activity, therefore key analogs would replace the guanidine functionality with 
other moieties that might enhance CNS exposure.  Thus, we piloted a number of typical, high 
yielding reactions (acylation, sulfonylation and urea formation) with 2.32 en route to unnatural 
analogs of 2.1 and 2.2.   
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Figure 2.8.1: Potential sites for analog development around 2.1. 
The first round of analogs were based on simple capping of the primary amine of 2.32 to 
afford amides (2.33 and 2.34) sulfonamide (2.35 and 2.36) and ureas (2.37 and 2.38) in place of 
the guanidine moiety of 2.1 (Figure 2.8.2).   
 
Figure 2.8.2: Library of unnatural analogs of 2.1 and 2.2 with alternative moieties replacing the 
guanidine. 
In an effort to add additional structural diversity, we developed chemistry to access N-
linked congeners of 2.1 and 2.2 (Scheme 2.8.1).   Here, indoles 2.21 and 2.21A were alkylated 
under microwave-assisted Finkelstein conditions, and following ester hydrolysis provided N-
linked acetic acids 2.39 and 2.40 in 76% isolated yields.  A HATU-mediated amide coupling with 
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2.12, subsequent thermal dehydration and Boc deprotection delivered the N-linked analogs 2.39 
and 2.40 of 2.1 and 2.2 in 45% yield over three steps. Guanidation and acidic Boc group removal 
rendered N-linked unnatural analogs 2.41 and 2.42.  Thus, the first unnatural analogs of 2.1 and 
2.2 have been synthesized in short order, with significant structural diversity. 
 
Scheme 2.8.1: Synthesis of N-linked Unnatural Analogs 2.41 and 2.42 of 2.1 and 2.2. 
2.9 Conclusion 
In conclusion, we completed the total synthesis of phidianidines A (2.1) and B (2.2), the 
first 1,2,4-oxadiazole-containing alkaloid, from the marine opisthobranch mollusk Phidiana 
militaris in six steps in 40% and 21% overall yields, respectively, from commercial materials.   
We explored multiple synthetic strategies toward the synthesis of 6-bromoindole-3-acetic acid 
(2.3).  Biological evaluation of 2.1 and 2.2 (including advanced intermediate 2.32) proved them 
devoid of cytotoxicity at high doses over 48 hours in HEK293 cells.  Importantly, receptor 
profiling efforts identified 2.1 and 2.2 as potent ligands for, and inhibitors of, DAT, with little or 
no activity at the highly homologous NET and SERT.  Even more exciting was the finding that 
2.1 and 2.2 were potent ligands for the -opioid receptor, with no activity at the - or -opioid 
receptors, and both displayed weak -opioid partial agonist activity.  These data, and those 
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generated with dispyrin 1.4 and (+)-7-bromotrypargine 1.7, argue well for the continued synthesis 
and profiling of marine natural products as new sources of potent and selective ligands for CNS 
targets of therapeutic relevance.  Moreover, the intriguing pharmacological profile of 2.1 and 2.2 
led us to then explore chemistry to access unnatural analogs, and we prepared eight structurally 
and topologically diverse congeners.   
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EXPERIMENTAL METHODS 
 
Synthesis: 
All reagents were purchased from Sigma‐Aldrich Corp., Matrix Scientific, Fisher 
Scientific, and Ark Pharm Inc., and were used without purification. Analytical thin‐layer 
chromatography (TLC) was performed on 250 μm silica gel plates from Sorbent Technologies. 
Visualization was accomplished via UV light, and/or the use of ninhydrin, I2, 2,4-
dinitrophenylhydrazine, and potassium permanganate solutions followed by application of heat. 
Chromatography was performed using Silica Gel 60 (230‐400 mesh) from Sorbent Technologies 
or Silica RediSep Rf flash columns on a CombiFlash Rf automated flash chromatography system. 
All 1H and 13C NMR spectra were recorded on Bruker AV‐400 (400 MHz), DRX-500 (500 MHz) 
and AV-600 (600 MHz) instruments. Chemical shifts are reported in ppm relative to residual 
solvent peaks as an internal standard set to δ 7.26 and δ 77.16 (CDCl3), δ 3.31 and δ 49.00 
(CD3OD), and δ 2.50 and δ 39.52 (d6-DMSO). Data are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = pentet br = broad, dd=doublet of 
doublets, dq=doublet of quartets, td = triplet of doublets, pd = pentet of doublets, m = multiplet), 
coupling constant (Hz), integration. Low resolution mass spectra (LCMS) were obtained on an 
Agilent 1200 LCMS with electrospray ionization. High resolution mass spectra (HRMS) were 
recorded on a Waters Qtof‐API‐US plus Acquity system with ES as the ion source. Analytical 
high pressure liquid chromatography (HPLC) was performed on an Agilent 1200 analytical 
LCMS with UV detection at 214 nm and 254 nm along with ELSD detection.  
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Tert-butyl (5-aminopentyl)carbamate  (2.10). 
Di-tert-butyl dicarbonate (2.8 mL, 12.23 mmol) in 50 mL of 9:1 dioxane/water was added to a 
solution of 1,5-diaminopentane 2.6 (5 g, 48.93 mmol) in 50 mL of 9:1 dioxane/water over a 
period of 3 hours. The solution was stirred at room temperature overnight and concentrated and 
the residue was taken up in 50 mL of water. The precipitated N,N'-di-Boc-1,5-diaminopentane 
was removed by filtration through a fritted glass funnel, and the filtrate was extracted with DCM 
(50 mLx4). The combined organic extracts were washed by water (20 mLx2), then dried by 
magnesium sulfate.  The dried organics were concentrated under reduced pressure, yielding 
(2.10) 2.14 g (22% by 1,5-diaminopentane, 80% by di-tert-butyl dicarbonate) as a colorless oil 
that solidified upon drying. 1H NMR (400 MHz, CDCl3, δ (ppm)): 4.68 (s, 1H) 3.05 (s, 2H), 2.63 
(q, J = 7.40 Hz, 2H), 1.38 (m, 15H), 1.28 (m, 2H), 1.13 (s, 1H); 13C NMR (150 MHz, d6-DMSO, 
δ (ppm)): 155.9, 79.8, 41.9, 40.3, 33.3, 29.8, 28.3, 23.9; HRMS (TOF, ES+)  C10H22N2O2 [M+H]+ 
m/z 203.1760, measured 203.1758. 
 
Tert-butyl (5-cyanamidopentyl)carbamate (2.11). 
Tert-butyl (5-aminopentyl)carbamate 2.10 (1.52 g, 7.51 mmol) was dissolved in 20 mL THF and 
sodium carbonate (2.38 g, 22.5 mmol) was added.  The resulting suspension was cooled to 0oC.  
Cyanogen bromide (3.15 g, 30.05 mmol) was added as a solution in 20 mL chloroform via 
addition funnel over the course of 30 minutes.  The solution was stirred 12 hours and monitored 
by thin layer chromatography.  Upon completion, the solution was transferred to a separatory 
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funnel and extracted 3X with 25 mL DCM.  The combined organic layers were dried over 
magnesium sulfate, filtered and concentrated under reduced pressure to yield a colorless oil.  The 
product was purified on silica (1:1 ethyl acetate:hexanes), yielded 1.32 g  (75%) of 2.11 as a 
colorless solid.  1H NMR (400.1 MHz, CD3OD, δ (ppm)): 4.67 (s, 1 H), 4.58 (t, J = 5.10 Hz, 1H), 
3.04 (m, 4H), 1.59 (m, 2H) 1.47 (m, 2H) 1.40 (m, 12H); 13C NMR (150 MHz, CD3OD, δ (ppm)): 
156.2, 116.7, 79.2, 45.8, 40.0, 29.5, 29.0, 28.6, 23.1  HRMS (TOF, ES+)  C11H21N3O2 [M+H]+ 
m/z 228.1712, measured 228.1710. 
 
Tert-butyl (5-(2-hydroxyguanidino)pentyl)carbamate (2.12). 
Tert-butyl (5-cyanamidopentyl)carbamate 2.11 (657 mg, 2.89 mmol) was dissolved in absolute 
ethanol.  Sodium bicarbonate (485 mg, 5.78 mmol) and hydroxylamine HCl (221 mg, 3.18 mmol) 
were added and the reaction was stirred at 25oC for 4 hours.  Product formation was monitored by 
thin layer chromatography (80:18:2 CHCl3:MeOH:NH4OH) visualized with I2 stain.  Upon 
consumption of starting material, the reaction mixture was concentrated and purified on silica 
(CHCl3 to 80:18:2 CHCl3:MeOH:NH4OH) and isolated 2.12 as a colorless solid 641 mg (85%).  
1H NMR (400.1 MHz, CDCl3) δ (ppm)): 5.75 (br m, 3H) 5.17 (S, 1H) 2.99 (m, 4H), 1.36 (m, 
13H), 1.27 (m, 2H); 13C NMR (150 MHz, CDCl3) δ (ppm)):156.5, 156.1, 78.9, 57.7, 49.9, 41.9, 
41.2, 40.3, 29.5, 29.1, 28.3, 23.9, 18.1; HRMS (TOF, ES+)  C11H24N4O3 [M+H]+ m/z 261.1927, 
measured 261.1926. 
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2-(6-bromo-1H-indol-3-yl)-2-oxoacetic acid (2.30). 
6-Bromoindole 2.21 (1 g, 5.1 mmol) was dissolved in 20 mL diethyl ether.  Oxalyl chloride (890 
uL, 10.2 mmol) was added and the reaction was stirred 45 minutes at 25oC.  H2O (500 uL, 25.5 
mmol) was added, followed by 50 mL diethyl ether.  The reaction was stirred 30 minutes and 
filtered via buchner funnel.  The solid was washed with diethyl ether and dried under high 
vacuum. Obtained 1.37 g (99.9%) 2.30 as a yellow solid.  1H NMR (400.1 MHz, d6-DMSO, δ 
(ppm)): 8.47 (d, J = 3.25, 1H), 8.12 (d, J = 8.50, 1H), 7.75 (d, J = 1.50, 1H), 7.42 (dd, J =1.50, 
8.50, 1H); 13C NMR (150 MHz, d6-DMSO, δ (ppm)):181.1, 165.3, 139.1, 137.9, 125.9, 125.0, 
123.1, 116.5, 115.7, 112.6; HRMS (TOF, ES+)  C10H6BrNO3 [M+H]+ m/z 267.9609, measured 
[M 79Br+H], [M 81Br+H] 267.9610, 269.9600. 
 
 
2-(6-bromo-1H-indol-3-yl)acetic acid (2.3). 
A microwave vial equipped with stir bar was charged with 2.30 (914 mg, 3.41 mmol) and 
dissolved in 17 mL 2-ethoxyethanol.  Hydrazine hydrate (829 uL, 17.05 mmol) was added and 
the vial was sealed and heated in a microwave reactor at 80oC for 15 minutes.  The vial was then 
unsealed and solid NaOMe (1.84 g, 34.1 mmol) was added.  The vial was again sealed and heated 
in the microwave at 160oC for 1 hour.  The vial contents were transferred to a 250 mL separatory 
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funnel, acidified with 1N HCl (25 mL) and partitioned between ethyl acetate and H2O.  The 
aqueous phase was extracted 3X and the combined organic phase was dried over magnesium 
sulfate.  The product was purified on silica (1:1 EtOAc+1%AcOH:Hex), yielded 717 mg (80%) 
of 2.3 as a beige solid. 1H NMR (400.1 MHz, CD3OD, δ (ppm)): 7.51 (s, 1H), 7.45 (d, J = 8.5 Hz, 
1H), 7.16 (s, 1H), 7.13 (dd, J =1.56, 8.50 Hz, 1H), 3.72 (s, 1H); 13C NMR (150 MHz, CD3OD, δ 
(ppm)): 174.7, 137.3, 126.1, 124.1, 121.5, 119.5, 114.3, 113.6, 107.8, 30.3; HRMS (TOF, ES+)  
C10H8BrNO2 [M+H]+ m/z 253.9817, measured [M 79Br+H], [M 81Br+H] 253.9815, 255.9792.    
 
2-(1H-indol-1-yl)acetic acid (2.40). 
A microwave vial equipped with stir bar was charged with indole 2.21A (1.0 g, 5.70 mmol) and 
dissolved in 15 mL acetonitrile.  2-Bromoethylacetate (11.41 mmol), K2CO3 (11.41 mmol), and 
KI (50 mg, cat) were added and the vial was sealed and heated in a microwave reactor at 160oC 
for 20 minutes.  The mixture was transferred to a 250 mL separatory funnel and partitioned 
between ethyl acetate and H2O.  The aqueous phase was extracted 3x with 25 mL ethyl acetate 
and the combined organic phase was dried over magnesium sulfate and concentrated under 
reduced pressure.  The crude product was dissolved in dioxane (10 mL) and treated with 1M 
NaOH (10 mL).  The reaction was stirred at 25oC for 3 hours and again transferred to a separatory 
funnel.  The mixture was acidified with 2N HCl (20 mL) and extracted 3x with 25 mL ethyl 
acetate.  The combined organic phase was dried over magnesium sulfate and concentrated under 
reduced pressure. The product was purified on silica (1:1 EtOAc+1%AcOH:Hex), yielded 987 
mg (76% over two steps) 2.40 as a beige solid. 1H NMR (400.1 MHz, d6-DMSO, δ (ppm)): 7.55 
(d, J = 7.80 Hz, 1H), 7.38 (d, J = 8.0Hz, 1H), 7.33 (d, J = 3.25 Hz, 1H), 7.12 (t, J =7.56 Hz, 1H), 
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7.029 (t, J = 7.56 Hz, 1H), 6.44 (d, J = 3.25 Hz, 1H) 5.00 (s, 2H); 13C NMR (150 MHz, CD3OD, 
δ (ppm)): 170.8, 136.7, 130.0, 128.4, 121.5, 120.6, 119.4, 110.1, 101.3, 47.4; HRMS (TOF, ES+)  
C10H8BrNO2 [M+H]+ m/z 176.0712, measured 176.0712.    
 
2-(6-bromo-1H-indol-1-yl)acetic acid (2.39). 
The procedure for 2.40 was followed, utilizing 6-Bromoindole as starting material.  1H NMR 
(400.1 MHz, d6-DMSO, δ (ppm)): 7.70 (s, 1H), 7.51 (d, J = 8.5 Hz, 1H), 7.36 (d, J = 3.25 Hz, 
1H), 7.17 (dd, J =1.56, 8.50 Hz, 1H), 6.84 (d, J = 3.25 Hz, 1H), 5.05 (s, 2H); 13C NMR (150 
MHz, d6-DMSO, δ (ppm)): 170.7, 137.7, 131.1, 127.5, 122.45, 114.5, 113.2, 101.7, 47.5; HRMS 
(TOF, ES+)  C10H8BrNO2 [M+H]+ m/z 253.9817, measured [M 79Br+H], [M 81Br+H] 253.9815, 
255.9792.    
 
(5-((1H-indol-3-yl)methyl)-1,2,4-oxadiazol-3-yl)pentane-1,5-diamine (2.31). 
A flask was charged with 2.4 (105 mg, 0.599 mmol), HATU (227.7 mg, 0.599 mmol), DIEA (174 
uL, 0.658 mmol) and DCM (2 mL).  The solution was stirred for 30 minutes and transferring via 
pipette, was added dropwise to a stirred solution of 2.12 (171 mg, 0.658 mmol) in DCM (2 mL).  
The reaction was stirred 1 hour and concentrated under reduced pressure.  The crude mixture was 
dissolved in DCE (5 mL).  The flask was fitted with a reflux condenser and the reaction was 
heated to 100oC for 1 hour.  The reaction mixture was cooled and a 1:1 solution of DCM:TFA (5 
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mL) was added.  The flask was heated to 50oC for 3 hours, monitoring reaction progress by 
LCMS.  The mixture was then transferred to a separatory funnel and partitioned between water 
and DCM.  The mixture was extracted 3x with 25 mL DCM and the combined organic phase was 
dried over magnesium sulfate and concentrated under reduced pressure.  The product was purified 
by reverse phase HPLC using acetonitrile and 0.1% TFA/water (gradient: 10:90 to 90:10), 
obtained 78 mg (45%) of 2.31 as a brown glassy solid.  1H NMR (400.1 MHz, CD3OD, δ (ppm)): 
7.53 (d, J = 8.25 Hz, 1H), 7.36 (d, J = 8.25 Hz, 1H), 7.21 (s, 1H), 7.11 (t, J = 7.50 Hz, 1H), 7.01 
(t, J = 7.50, 1H), 4.22 (s, 2H), 3.16 (t, J = 7.0, 2H), 2.89 (m, 2H), 1.65 (m, 4H), 1.44 (m, 2H); 13C 
NMR (150 MHz, CD3OD, δ (ppm)): 177.7, 168.6, 126.6, 123.2, 121.2, 118.6, 117.7, 110.9, 
106.6, 42.1, 39.1, 28.1, 26.6, 23.1, 22.5; HRMS (TOF, ES+)  C16H21N5O [M+H]+ m/z 300.1824, 
measured 300.1823. 
 
5-((6-bromo-1H-indol-3-yl)methyl)-1,2,4-oxadiazol-3-yl)pentane-1,5-diamine (2.32). 
A flask was charged with 2.3 (105 mg, 0.599 mmol), HATU (227.7 mg, 0.599 mmol), DIEA (174 
uL, 0.658 mmol) and DCM (2 mL).  The solution was stirred for 30 minutes and transferring via 
pipette, was added dropwise to a stirred solution of 2.12 (171 mg, 0.658 mmol) in DCM (2 mL).  
The reaction was stirred 1 hour and concentrated under reduced pressure.  The crude mixture was 
dissolved in DCE (5 mL).  The flask was fitted with a reflux condenser and the reaction was 
heated to 100oC for 1 hour.  The reaction mixture was cooled and a 1:1 solution of DCM:TFA (5 
mL) was added.  The flask was heated to 50oC for 3 hours, monitoring reaction progress by 
LCMS.  The mixture was then transferred to a separatory funnel and partitioned between water 
and DCM.  The mixture was extracted 3x with 25 mL DCM and the combined organic phase was 
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dried over magnesium sulfate and concentrated under reduced pressure.  The product was purified 
by reverse phase HPLC using acetonitrile and 0.1% TFA/water (gradient: 10:90 to 90:10), 
obtained 119 mg (74%) of 2.32 as a brown glassy solid.  1H NMR (400.1 MHz, CD3OD, δ 
(ppm)): 7.51 (s, 1H), 7.44 (d, J = 8.50 Hz, 1H), 7.22 (s, 1H), 7.12 (d, J = 8.50 Hz, 1H), 4.18 (s, 
2H), 3.16 (t, J = 7.0 Hz, 2H), 2.88 (t, J = 7.50 Hz, 2H), 1.66 (m, 4H), 1.42 (m, 2H); 13C NMR 
(150 MHz, d6-DMSO, δ (ppm)):176.7, 168.5, 137.0, 125.7, 125.2, 121.4, 120.1, 114.2, 113.9, 
107.2, 45.2, 42.1, 27.9, 26.5, 23.2, 22.5; HRMS (TOF, ES+)  C16H20BrN5O [M+H]+ m/z 
378.0929, measured [M 79Br+H], [M 81Br+H] 378.0926, 380.0911. 
 
Phidianidine A (2.1).  
A 50 mL round bottom flask was charged with 2.32 (20 mg, 0.0528 mmol), DIEA (20 uL), N,N’-
Bis(Boc)-1H-pyrazole-1-carboxamidine (17.69 mg, 0.058 mmol), and DCM (5 mL).  The 
reaction was stirred 30 minutes, monitoring progress by LCMS.  After completion, a 1:1 solution 
of DCM:TFA (5 mL) was added and the reaction was stirred 8 hours.  The mixture was then 
transferred to a separatory funnel, washed with water and extracted 3 times with DCM.  The 
combined organic phase was dried over magnesium sulfate before being concentrated under 
reduced pressure.  The brown solid was then purified by reverse phase HPLC using acetonitrile 
and 0.1% TFA/water (gradient: 10:90 to 90:10), obtained 20 mg (90%) of 2.1 as a glassy golden 
brown solid.  1H NMR (600 MHz, d6-DMSO, δ (ppm)): 11.18 (s, 1H), 7.56 (d, J = 1.80 Hz, 1H), 
7.47 (d, J = 8.50 Hz, 1H), 7.34 (d, J = 2.50, 1H),  7.13 (dd, J = 8.50, 1.78, 1H), 6.72 (t, J = 5.85 
Hz, 1H), 4.2 (s, 2H), 3.00 (dq, J = 33.1, 7.0 Hz, 4H) 1.46 (m, 4H), 1.27 (m, 2H); 13C NMR (150 
MHz, d6-DMSO, δ (ppm)): 177.1, 168.9, 157.1, 137.4, 126.1, 125.7, 122.0, 120.6, 114.5, 114.4, 
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107.8, 42.6, 41.0, 28.54, 28.53, 23.8, 22.9; HRMS (TOF, ES+) C17H22BrN7O [M+H]+ m/z 
420.1147, measured [M 79Br+H], [M 81Br+H] 420.1148, 422.1132. 
 
Phidianidine B (2.2).  
A 50 mL round bottom flask was charged with 2.31 (20 mg, 0.0668 mmol), DIEA (20 uL), N,N’-
Bis(Boc)-1H-pyrazole-1-carboxamidine (23.0 mg, 0.073 mmol), and DCM (5 mL).  The reaction 
was stirred 30 minutes, monitoring progress by LCMS.  After completion, a 1:1 solution of 
DCM:TFA (5 mL) was added and the reaction was stirred 8 hours.  The mixture was then 
transferred to a separatory funnel, washed with water and extracted 3 times with DCM.  The 
combined organic phase was dried over magnesium sulfate before being concentrated under 
reduced pressure.  The brown solid was then purified by reverse phase HPLC using acetonitrile 
and 0.1% TFA/water (gradient: 10:90 to 90:10), obtained 20 mg (78%) 2.2 as a glassy brown 
solid.  1H NMR (400 MHz, d6-DMSO, δ (ppm)): 11.0, 7.51 (d, J = 7.85 Hz, 1H), 7.37 (d, J = 8.10 
Hz, 1H) 7.31 (d, J  = 2.45 Hz, 1H), 7.08-6.99 (dt, J = 58.2, 8.0 Hz, 2H), 6.71 (br t, J = 5.30 Hz, 
1H),  4.19 (s, 2H), 3.07-3.00 (m, 4H), 1.50-1.43 (m, 4H), 1.29-1.27 (m, 2H); 13C NMR (100 
MHz, d6-DMSO, δ (ppm)):177.3, 168.9, 157.1, 136.5, 127.2, 124.5, 121.6, 119.0, 118.7, 111.9, 
107.3, 42.7, 41.0, 28.57, 28.55, 23.8, 23.1; HRMS (TOF, ES+) C17H23N7O [M+H]+ m/z 342.2042, 
measured 342.2041. 
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N-(5-((5-((6-bromo-1H-indol-3-yl)methyl)-1,2,4-oxadiazol-3-
yl)amino)pentyl)cyclopropanecarboxamide (2.33). 
A 10 mL round bottom flask was charged with 2.32 (10 mg, 0.026 mmol), cyclopropanecarbonyl 
chloride (5 uL, 0.053 mmol), triethylamine (10 uL) and DCM (2 mL).  The flask was stirred for 3 
hours, monitoring by LCMS.  After 3 hours, water (3 mL) and DCM (2 mL) were added and the 
biphasic solution was stirred vigorously before being passed through an Isolute phase separator.  
The resulting organic layer was then concentrated and purified by reverse phase HPLC using 
acetonitrile and 0.1% TFA/water (gradient: 10:90 to 90:10). Isolated 10 mg (85%) of 2.33 as an 
off white solid.  1H NMR (600.1 MHz, CD3OD, δ (ppm)): 7.51 (d, J = 1.70, 1H), 7.45 (d, J = 8.50 
Hz, 1H), 7.22 (s, 1H), 7.126 (dd, J = 8.50, 1.70, 1H), 4.19 (s, 2H), 3.13 (dt, J = 17.83, 7.13 Hz, 
4H), 1.58 (m, 2H), 1.50 (m, 3H), 1.36 (m, 2H), 0.080 (m, 2H), 0.693 (m, 2H) ; 13C NMR (150 
MHz, CD3OD, δ (ppm)): 177.4, 174.9, 168.6, 137.4, 125.7, 124.2, 121.7, 119.3, 114.7, 113.8, 
107.2, 42.4, 38.9, 28.7, 28.3, 23.7, 22.4, 13.3, 5.6; HRMS (TOF, ES+)  C20H24BrN5O2 [M+H]+ 
m/z 446.1192, measured [M 79Br+H], [M 81Br+H] 446.1196, 448.1181.  
 
N-(5-((5-((6-bromo-1H-indol-3-yl)methyl)-1,2,4-oxadiazol-3-
yl)amino)pentyl)cyclohexanecarboxamide (2.34). 
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A 10 mL round bottom flask was charged with 2.32 (10 mg, 0.026 mmol), 
cyclohexanecarbonylchloride (5 uL mg, 0.057 mmol), triethylamine (10 uL) and DCM (2 mL).  
The flask was stirred for 3 hours, monitoring by LCMS.  After 3 hours, water (3 mL) and DCM 
(2 mL) were added and the biphasic solution was stirred vigorously before being passed through 
an Isolute phase separator.  The resulting organic layer was then concentrated and purified by 
reverse phase HPLC using acetonitrile and 0.1% TFA/water (gradient: 10:90 to 90:10).  Isolated 9 
mg (70%) of 2.34 as an off white solid.  1H NMR 600.1 MHz, CD3OD, δ (ppm)):7.54 (d, J = 1.70 
Hz, 1H), 7.48 (d, J = 8.50 Hz, 1H), 7.25 (s, 1H), 7.157 (dd, J = 8.50, 1.70, 1H), 4.21 (s, 2H), 3.15 
(m, 4H), 2.14 (m, 2H), 1.79 (m, 4H), 1.69 (m, 1H), 1.61 (dp, J = 56.7, 7.33, 4H), 1.46-1.21 (m, 
8H); 13C NMR (150 MHz, CD3OD, δ (ppm)) 177.7, 177.4, 168.6, 137.4, 125.7, 124.2, 121.7, 
119.3, 114.7, 113.8, 107.2, 45.1, 45.1, 42.4, 38.7, 38.5, 29.3, 28.6, 28.3, 25.4, 25.3, 23.6, 22.4; 
HRMS (TOF, ES+)   C23H30BrN5O2 [M+H]+ m/z 488.1661, measured [M 79Br+H], [M 81Br+H] 
488.1664, 490.1648. 
 
 
1-(5-((5-((6-bromo-1H-indol-3-yl)methyl)-1,2,4-oxadiazol-3-yl)amino)pentyl)-3-(4-
methoxyphenyl)urea (2.37). 
A 10 mL round bottom flask was charged with 2.32 (10 mg, 0.026 mmol), 4-
methoxyphenylisocyanate (5 uL, 0.057 mmol), triethylamine (10 uL) and DCM (2 mL).  The 
flask was stirred for 3 hours, monitoring by LCMS.  After 3 hours, water (3 mL) and DCM (2 
mL) were added and the biphasic solution was stirred vigorously before being passed through an 
Isolute phase separator.  The resulting organic layer was then concentrated and purified by 
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reverse phase HPLC using acetonitrile and 0.1% TFA/water (gradient: 10:90 to 90:10).  Isolated 
10 mg (73%) of 2.37 as a brown solid.  1H NMR (600.1 MHz, d6-DMSO, δ (ppm)): 11.16 (s, 1H), 
8.17 (s, 1H), 7.50 (d, J = 1.70 Hz, 1H), 7.47 (d, J = 8.50 Hz, 1H), 7.35 (d, J = 2.50 Hz, 1H), 7.27 
(dd, J = 8.90, 0.87 Hz, 2H), 7.14 (dd, 8.50, 1.85 Hz, 1H), 6.78 (m, 3H), 4.20 (s, 2H), 3.68 (s, 3H), 
3.01 (m, 4H),1.50 (m, 2H), 1.40 (m, 2H), 1.27 (m, 2H); 13C NMR (150 MHz, d6-DMSO, δ 
(ppm)): 177.1, 168.9, 168.9, 155.8, 155.7, 154.2, 137.4, 134.1, 134.0, 126.2, 125.7, 123.5, 122.0, 
120.6, 119.7, 119.6, 114.5, 114.4, 114.2, 107.8, 55.5, 42.8, 42.7, 29.9, 28.7, 24.1, 22.9,  ; HRMS 
(TOF, ES+)  C24H27BrN6O3 [M+H]+ m/z 527.1406, measured [M 79Br+H], [M 81Br+H] 
527.1405,529.1391. 
 
1-(5-((5-((6-bromo-1H-indol-3-yl)methyl)-1,2,4-oxadiazol-3-yl)amino)pentyl)-3-(p-tolyl)urea 
(2.38). 
A 10 mL round bottom flask was charged with 2.32 (10 mg, 0.026 mmol), p-Tolylisocyanate (5 
uL, 0.057 mmol), triethylamine (10 uL) and DCM (2 mL).  The flask was stirred for 3 hours, 
monitoring by LCMS.  After 3 hours, water (3 mL) and DCM (2 mL) were added and the 
biphasic solution was stirred vigorously before being passed through an Isolute phase separator.  
The resulting organic layer was then concentrated and purified by reverse phase HPLC using 
acetonitrile and 0.1% TFA/water (gradient: 10:90 to 90:10).  Isolated 8 mg (60%) of 2.38 as a 
brown solid.  1H NMR (600.1 MHz, d6-DMSO, δ (ppm)): 11.16 (s, 1H), 8.17 (s, 1H), 7.50 (d, J = 
1.70 Hz, 1H), 7.47 (d, J = 8.50 Hz, 1H), 7.35 (d, J = 2.50 Hz, 1H), 7.27 (dd, J = 8.90, 0.87 Hz, 
2H), 7.14 (dd, 8.50, 1.85 Hz, 1H), 6.78 (m, 3H), 4.20 (s, 2H), 3.01 (m, 4H), 2.68 (s, 3H), 1.50 (m, 
2H), 1.40 (m, 2H), 1.27 (m, 2H); 13C NMR (150 MHz, d6-DMSO, δ (ppm)): 177.1, 168.9, 168.9, 
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155.8, 155.7, 154.2, 137.4, 134.1, 134.0, 126.2, 125.7, 1235, 122.0, 120.6, 119.7, 119.6, 114.5, 
114.4, 114.2, 107.8, 45.5, 42.8, 42.7, 29.9, 28.7, 24.1, 22.9,  HRMS (TOF, ES+)  C24H27BrN6O2 
[M+H]+ m/z 510.1441, measured [M 79Br+H], [M 81Br+H] 510.1445, 512.1458. 
 
2-bromo-N-(5-((5-((6-bromo-1H-indol-3-yl)methyl)-1,2,4-oxadiazol-3-
yl)amino)pentyl)benzenesulfonamide (2.35). 
A 10 mL round bottom flask was charged with 2.32 (10 mg, 0.026 mmol), 2-
bromophenylsulfonylchloride (10 mg, 0.057 mmol), triethylamine (10 uL) and DCM (2 mL).  
The flask was stirred for 3 hours, monitoring by LCMS.  After 3 hours, water (3 mL) and DCM 
(2 mL) were added and the biphasic solution was stirred vigorously before being passed through 
an Isolute phase separator.  The resulting organic layer was then concentrated and purified by 
reverse phase HPLC using acetonitrile and 0.1% TFA/water (gradient: 10:90 to 90:10).  Isolated 9 
mg (58%) of 2.35 as an off white glassy solid.  1H NMR (600.1 MHz, CD3OD, δ (ppm)): 8.08 
(dd, 7.83, J = 1.70 Hz, 1H, 7.75 (dd, J = 7.83, 1.15 Hz, 1H), 7.54 (d, J = 1.70 Hz, 1H), 7.49 (td, J 
= 7.50, 1.50), 7.48 (d, J = 8.50 Hz, 1H), 7.42 (dt, J = 7.75, 1.75 Hz, 1H), 7.26 (s, 1H), 7.16 (dd, 
8.50, 1.75), 4.60 (s, 2H), 4.22 (s, 2H), 3.06-2.90 (dt, J = 92.7, 7.0 Hz, 4H), 1.49-1.42 (m, 4H), 
1.31 (m, 2H); 13C NMR (150 MHz, CD3OD, δ (ppm)): 177.5, 168.5, 139.6, 137.4, 135.0, 133.3, 
130.8, 127.4, 125.7, 124.3, 121.8, 119.4, 114.7, 113.8, 107.2, 42.3, 28.7, 28.1, 23.3, 22.4; HRMS 
(TOF, ES+)  C22H23Br2N5O3S  [M+H]+ m/z 595.9967, measured 595.9966. 
 
 
 63 
 
 
N-(5-((5-((6-bromo-1H-indol-3-yl)methyl)-1,2,4-oxadiazol-3-yl)amino)pentyl)-3,4-
dimethoxybenzenesulfonamide (2.36). 
A 10 mL round bottom flask was charged with 2.32 (10 mg, 0.026 mmol), 3,4-
dimethoxyphenylsulfonylchloride (10 mg, 0.057 mmol), triethylamine (10 uL) and DCM (2 mL).  
The flask was stirred for 3 hours, monitoring by LCMS.  After 3 hours, water (3 mL) and DCM 
(2 mL) were added and the biphasic solution was stirred vigorously before being passed through 
an Isolute phase separator.  The resulting organic layer was then concentrated and purified by 
reverse phase HPLC using acetonitrile and 0.1% TFA/water (gradient: 10:90 to 90:10).  Isolated 
10 mg (66%) 2.36 as an off white glassy solid.  1H NMR (600.1 MHz, CD3OD, δ (ppm)): 7.54 (s, 
1H), 7.47 (d, J = 8.50 Hz, 1H), 7.45 (dd, J =8.50, 2.20 Hz, 1H), 7.36 (d, J = 2.20 Hz, 1H), 7.25 (s, 
1H), 7.15 (dd, J = 8.50, 1.70 Hz, 1H), 7.05 (d, J = 8.50 Hz, 1H), 4.22 (s, 2H), 3.88 (d, J = 5.35 
Hz, 6H), 3.09 (t, J = 7.0 Hz, 4H), 2.88 (t, J = 7.0 Hz, 4H),  1.54-1.44 (m, 4H), 1.33 (m, 2H); 13C 
NMR (150 MHz, CD3OD, δ (ppm)): 177.5, 168.5, 152.5, 149.1, 137.4, 1319, 125.7, 124.2, 121.8, 
120.5, 119.3, 114.7, 113.8, 110.5, 109.4, 107.2, 55.19, 55.14, 42.4, 42.3, 28.6, 28.1, 23.4, 22.4; 
HRMS (TOF, ES+) C24H28BrN5O5S [M+H]+ m/z 578.1073, measured [M 79Br+H], [M 81Br+H] 
578.1074, 580.1061. 
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1-(5-((5-((6-bromo-1H-indol-1-yl)methyl)-1,2,4-oxadiazol-3-yl)amino)pentyl)guanidine 
(2.41). 
A flask was charged with 2.40 (100 mg, 0.393 mmol), HATU (150 mg, 0.393 mmol), DIEA (70 
uL, 0.393 mmol) and DCM (2 mL).  The solution was stirred for 30 minutes and transferring via 
pipette, added dropwise to a stirred solution of 2.12 (112 mg, 0.432 mmol) in DCM (2 mL).  The 
reaction was stirred 1 hour and concentrated under reduced pressure.  The crude mixture was 
dissolved in DCE (5 mL).  The flask was fitted with a reflux condenser and the reaction was 
heated to 100oC for 1 hour.  The reaction mixture was cooled and a 1:1 solution of DCM:TFA (5 
mL) was added.  The flask was heated to 50oC for 3 hours, monitoring reaction progress by 
LCMS.  The mixture was then transferred to a separatory funnel and partitioned between water 
and DCM.  The mixture was extracted 3x with 25 mL DCM and the combined organic phase was 
dried over magnesium sulfate and concentrated under reduced pressure.  The crude mixture was 
dissolved in DCM and N,N’-Bis(Boc)-1H-pyrazole-1-carboxamidine (134 mg, 0.432 mmol) was 
added.  The reaction was stirred 1 hour and a 1:1 solution of DCM:TFA (10 mL) was added.  The 
reaction was heated to 80oC for 3 hours.  The mixture was then transferred to a separatory funnel 
and partitioned between water and DCM.  The mixture was extracted 3x with 25 mL DCM and 
the combined organic phase was dried over magnesium sulfate and concentrated under reduced 
pressure.  The product was purified by reverse phase HPLC using acetonitrile and 0.1% 
TFA/water (gradient: 10:90 to 90:10), obtained 112 mg (67%) 2.41 as a bright red glassy solid.  
1H NMR (600.1 MHz, CD3OD, δ (ppm)): 7.58 (s, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.25 (d, J = 3.25 
Hz, 1H), 7.14 (dd, J = 8.50, 1.56 Hz, 1H), 6.49 (d, J = 3.25 Hz, 1H), 5.46 (s, 2H), 3.10 (m, 4H), 
1.55 (m, 6H), 1.35 (m, 2H); 13C NMR (150 MHz, CD3OD, δ (ppm)):157.9, 167.0, 135.8, 124.1, 
 65 
 
122.6, 120.2, 117.7, 113.1, 112.2, 105.6, 40.5, 37.5, 26.5, 25.1, 21.6, 20.8; HRMS (TOF, ES+)  
C17H22BrN7O [M+H]+ m/z 420.1147, measured [M 79Br+H], [M 81Br+H] 420.1148, 422.1126. 
 
1-(5-((5-((1H-indol-1-yl)methyl)-1,2,4-oxadiazol-3-yl)amino)pentyl)guanidine (2.42). 
A flask was charged with 2.41 (100 mg, 0.292 mmol), HATU (111 mg, 0.292 mmol), DIEA (101 
uL, 0.584mmol) and DCM (2 mL).  The solution as stirred for 30 minutes and transferring via 
pipette, added dropwise to a stirred solution of 2.12 (112 mg, 0.432 mmol) in DCM (2 mL).  The 
reaction was stirred 1 hour and concentrated under reduced pressure.  The crude mixture was 
dissolved in DCE (5 mL).  The flask was fitted with a reflux condenser and the reaction was 
heated to 100oC for 1 hour.  The reaction mixture was cooled and a 1:1 solution of DCM:TFA (5 
mL) was added.  The flask was heated to 50oC for 3 hours, monitoring reaction progress by 
LCMS.  The mixture was then transferred to a separatory funnel and partitioned between water 
and DCM.  The mixture was extracted 3x with 25 mL DCM and the combined organic phase was 
dried over magnesium sulfate and concentrated under reduced pressure.  The crude mixture was 
dissolved in DCM and N,N’-Bis(Boc)-1H-pyrazole-1-carboxamidine (100 mg, 0.321 mmol) was 
added.  The reaction was stirred 1 hour and a 1:1 solution of DCM:TFA (10 mL) was added.  The 
reaction was heated to 80oC for 3 hours.  The mixture was then transferred to a separatory funnel 
and partitioned between water and DCM.  The mixture was extracted 3x with 25 mL DCM and 
the combined organic phase was dried over magnesium sulfate and concentrated under reduced 
pressure.  The product was purified by reverse phase HPLC using acetonitrile and 0.1% 
TFA/water (gradient: 10:90 to 90:10), obtained 32 mg (32%) 2.42 as a beige glassy solid.  1H 
NMR (600.1 MHz, CD3OD, δ (ppm)): 7.61 (d, J = 7.80 Hz, 1H), 7.44 (d, J = 8.0Hz, 1H), 7.36 (d, 
J = 3.25 Hz, 1H), 7.22 (t, J =7.56 Hz, 1H), 7.11 (t, J = 7.56 Hz, 1H), 6.55 (d, J = 3.25 Hz, 1H) 
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5.58 (s, 2H); 3.14 (m, 4H), 1.59 (m, 4H), 1.40 (m, 2H); 13C NMR (150 MHz, CD3OD, δ 
(ppm)):174.1, 168.8, 157.1, 157.0, 436.3, 128.9, 128.6, 121.7, 120.7, 119.7, 109.4, 102.1, 42.4, 
41.2, 40.9, 28.2, 28.1, 23.5; HRMS (TOF, ES+)  C17H23N7O [M+H]+ m/z 342.2042, measured 
342.2042. 
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Table 2.9.1: NMR Shift Correlation Tables for 2.1 and 2.2.   
1H 
Natural Synthetic Natural Synthetic 
PA-A 2.1 PA-A 2.1 PA-B 2.2 PA-B 2.2 
11.15 11.18 11.00 11.0 
7.35 7.34 7.31 7.31 
7.53 7.47 7.50 7.51 
7.13 7.13 6.99 6.99 
7.56 7.56 7.09 7.08 
4.2 4.20 7.36 7.37 
6.72 6.72 4.20 4.19 
2.99 3.00 6.71 6.71 
1.36-1.56 1.40-1.52 3.00 3.01 
1.28 1.27 1.36-1.56 1.42-1.52 
1.36-1.56 1.40-1.52 1.28 1.28 
3.02 3.00 1.36-1.56 1.42-1.52 
7.41 7.40 3.05 3.01 
7.43 7.49 
13C 
Natural Synthetic Natural Synthetic 
PA-A 2.1 PA-A 2.1 PA-B 2.2 PA-B 2.2 
125.0 125.7 125.3 124.50 
106.8 107.8 103.9 107.30 
125.2 126.1 126.7 127.20 
120.0 120.6 117.3 118.70 
121.3 122.0 117.6 121.60 
113.5 114.4 120.2 119.00 
114.1 114.5 111.5 111.90 
137.0 137.4 136.1 136.50 
22.5 22.9 22.7 23.10 
168.5 168.9 168.5 168.90 
176.7 177.1 176.9 177.30 
40.5 41 40.7 41.00 
28.1 28.5 28.1 28.57 
23.4 23.8 23.4 23.80 
28.1 28.54 28.1 28.55 
41.9 42.6 42.3 42.70 
156.6 157.1 156.6 157.10 
 
Tables formatted to match Phidianidines A & B isolation NMR data tables by Carbone et al. 
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Cell proliferation/cytotoxicity assay:   
Cytotoxicity assays were performed in HEK293 cells using a WST-1 cell proliferation assay kit at 
both 24 and 48 hour time points.  25,000 cells were plated in a 96-well plate in 100 mL of culture 
medium with either DMSO, 2.1 (10 M) or 2.2 (10 M).   Cells were then cultured for either 24 
or 48 hours in a CO2 incubator at 37 oC.  Then, 10 mL of WST-1 mixture added to each well, 
mixed on orbital shaker and cells incubated for another 2 hours at 37 oC.  The absorbance of each 
sample was then measured at 450 nm. 
Radioligand Binding and Functional assays: 
All biological assays were conducted at Ricerca Pharma according to published protocols and 
each assay employed established control compounds27,54. 
Functional OR assay (GTPS)27,54: 
Human recombinant -opioid receptors stably expressed in CHO-K1 cells were used. 
Compounds 2.1, 2.2 and 2.32 were preincubated with the membranes (0.016 mg/ml‡) and 3 mM 
GDP in modified HEPES pH 7.4 buffer for 20 minutes at 25C and SPA beads were then added 
for another 60 minutes at 30°C. The reaction was initiated by 0.3 nM [35S]GTPS for an 
additional 30 minute incubation period. Test compound-induced increase of [35S]GTPS binding 
by 50 percent or more (50%) relative to the 10 mM DAMGO response indicates possible OR 
agonist activity. Compounds are screened at 10, 1, 0.1, 0.01 and 0.001 mM.    
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Figure 3.1.3: Chemical structure of non-fluorescent Fluo-4 AM and Fluo-4.  The four 
acetoxymethyl esters on Fluo-4 AM are cleaved inside cells to yield Fluo-4, which fluoresces 
upon binding to Ca2+ ions58. 
While a number of recent publications have highlighted members of the group II and III 
mGluRs as potential new targets for the treatment of schizophrenia and Parkinsons disease, 
several new findings have shown a potential link between mutations in the mGlu1 gene cluster 
and schizophrenia59,60.   
Schizophrenia is a devastating neurological disorder that affects roughly 1% of the 
population, though its neurobiological cause remains unknown.  Current pharmacological studies 
suggest two potential models: the ‘dopamine hypothesis’ based on the knowledge that most of the 
currently available antipsychotic agents function as dopamine antagonists61 and the ‘glutamate 
hypothesis’ which was proposed based on the observation that animals treated with NMDA 
receptor (N-methyl-D-aspartate, an ionotropic glutamate receptor) antagonists demonstrate 
schizophrenia-like symptoms of psychosis62,63.   
3.2 Background 
In order to probe the role of glutamate receptors in schizophrenia and bipolar disorder, 
Frank and coworkers performed a genetic screen of 10 “hub” genes of 1344 individuals divided 
into three groups: those with schizophrenia (503), those with bipolar disorder (263), and healthy 
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receptor activity could play an essential role in schizophrenia, bipolar disorder, and other CNS 
pathologies.   
3.3 Prior Art - mGlu1 PAMs 
A potent and selective mGlu1 positive allosteric modulator would be an ideal tool to 
restore decreased mutant signaling to wild type levels without constitutively activating the 
receptor through agonism.  A recent literature review66 notes that all of the currently available 
subtype selective mGlu1 PAMs were generated at Roche Pharmaceuticals and Vanderbilt (Table 
3.3.1).  While all of the five compounds are active at the rat mGlu1 isoform, only two compounds 
show activity at human mGlu1: Ro 67-4853 (3.3) and Ro 07-11401 (3.5)67,68. 
Table 3.3.1: Prior art - mGlu1 PAMs. 
O
H
NO
O
O
H
NO
O
O
O
H
N
O
N
N N
H
O
N
S
O O
F
N
O
F3C
3.2
3.3
3.4
3.5
3.6
Compound Structure Potency/Affinity (EC50) References
200 nM
69 nM
174 nM
2.4 uM
56 nM
Knoflach et al., 2001
Knoflach et al., 2001
Knoflach et al., 2001
Hemstapat et al., 2006
Knoflach et al., 2001
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Both 3.3 and 3.5 show good potency/efficacy at mGlu1, however, their utility as tool 
compounds is limited due to poor DMPK profiles.  Compound 3.3 features a carbamate moiety 
which is easily hydrolyzed under aqueous in vitro conditions.  Additionally, the xanthene moiety 
which is common to both structures renders them each highly lipophilic and likely to engage in 
nonspecific binding.  Indeed, in vitro plasma protein binding analysis of 3.5 by the Daniels 
laboratory at Vanderbilt shows that only 0.1% of the dosed compound exists as free fraction in rat 
serum.  With so little unbound compound in solution, the chances of drug-target interaction are 
significantly diminished.  Finally, 3.5 was shown to inhibit CYP 2C9 at an IC50 of 600 nM.  All 
of these data combine to show that, while several mGlu1 PAMs have been identified, their utility 
as tool compounds is highly limited.  A potent, selective, and stable hmGlu1 PAM is needed to 
probe the effects of potentiating the decreased mGlu1 signaling in the schizophrenia mutations 
described in the Frank and Ayoub genetic studies. 
3.4 hmGlu1 PAM First Attempt: VU-71/48 Scaffolds 
Due to the lack of suitable selective mGlu1 PAMs, we initiated a synthesis campaign to 
generate our own ligand by further exploring and optimizing the structure activity relationships of 
aminopyrazole-based compounds VU-71 (3.6) and VU-48 (3.7) at hmGlu1 (Figure 3.4.1).  These 
compounds represent the most selective (3.6) and potent (3.7) mGlu1 potentiators reported in the 
2006 Molecular Pharmacology article from the Conn laboratory at Vanderbilt68.  
 
Figure 3.4.1: Structures of VU-71 (3.6), VU-48 (3.7), and CDPPB (3.8). 
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number of different heterocycles, including pyradines, pyrazine, pyrimidines, furans, oxazoles, 
and thiazoles.  A total of 75 compounds were synthesized in three libraries.   
 
Scheme 3.4.1: Matrix based synthesis of VU-71/VU-48 analogs. 
In order to test the newly-synthesized compounds at the human mGlu1, collaborators in 
the Conn laboratory generated tetracycline-inducible human mGlu1 in TREx293 cells, and also 
remade rat mGlu1 in the same cell background.  As noted above, the 2006 Mol. Pharm. 
publication reported EC50 potency values of 2.4 µM and 460 nM for 3.6 and 3.7, respectively.   
These values were measured in Ca2+ fluorescence assays using BHK cells stably expressing rat 
mGlu1.  Importantly, the compounds were not previously tested at human mGlu1. Thus, each of 
the newly generated libraries was initially screened in Ca2+ fluorescence assays in human mGlu1-
TREx293 cells.  Unfortunately, no chemical modification of the 3.6/3.7 scaffolds engendered 
hmGlu1 PAM activity (Figure 3.4.3). 
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Figure 3.4.4: Singlepoint screen (1 of 3 for 3.6/3.7 analog library) at 10 µM compound 
concentration against rmGlu1.  Compounds of note: VU0469806 (3.7) and VU0467832 (3.5). 
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Figure 3.4.5: Singlepoint screen (2 of 3 for 3.6/3.7 analog library) at 10 µM compound 
concentration against rmGlu1.   
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Figure 3.4.6: Singlepoint screen (3 of 3 for 3.6/3.7 analog library) at 10 µM compound 
concentration against rmGlu1.   
The relatively poor performance of the 3.6/3.7 analog library lead us to revisit the parent 
compounds.  As stated above, the 2006 Mol. Pharm. article highlighted EC50 potency values of 
2.4 μM and 460 nM for 3.6 and 3.7, respectively, in rmGlu1-BHK cells. When a concentration-
response curve was generated for 3.7 in rmGlu1-TREx293 cells, the EC50 value was found to be 
over 2.3 μM (Figure 3.4.7).   
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Figure 3.5.1: Representative members of the two VCNDD hmGlu4 PAM series with good 
efficacy at hmGlu1. 
Of the two structural series, we viewed compound 3.15 as the more desirable lead for 
library synthesis for several reasons: its potency at hmGlu1 was excellent, the original mGlu4 
series was well tolerate in in vitro experiments, and finally its hmGlu4 activity was found to be 
strongly linked to the eastern 2-pyridine moiety.  In previous work, removing the 2-pyridine 
caused mGlu4 potency to decrease dramatically70.  Contrastingly, 3.14 features an oxime moiety, 
which is easily hydrolyzed to a highly electrophilic α-cyclopropyl ketone under aqueous 
conditions.  This electrophilic center would be easily attacked by cellular nucleophiles.  
Additionally, the presence of the cyclopropane ring severely limits the amenability of this 
scaffold to library synthesis.  With these data in mind, we focused our attention on the 3.15 
scaffold. 
As mentioned previously, the 3.15 scaffold originated from the hmGlu4 PAM 
development project within the VCNDD.  High throughput screening hits 3.16 and 3.17 (Figure 
3.5.2) served as lead compounds for multiple rounds of synthesis to arrive at the present 
structures.  These HTS hits represented good starting points for probe development as they were 
relatively low molecular weight with no undesirable functional groups and were easily assembled 
from commercially available materials. 
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Figure 3.5.2: HTS hits that lead to the development of the 3.15 scaffold. 
Some initial SAR around the 3.15 scaffold was available at the outset of this new line of 
investigation into an hmGlu1 PAM.  Figure 3.5.3 highlights the data that had been previously 
generated around the western portion of this scaffold.  While functionalizing the phthalamide ring 
proved to slightly modulate the activity levels at both hmGlu1 and hmGlu4, any attempts at 
saturating the phthalamide phenyl ring, either partially or fully, caused steep declines in activity 
levels at both isoforms of the receptor.  The planar orientation of the phthalamide phenyl ring was 
also shown to be critical, as a disconnected phenyl ring that is free to rotate in space resulted in a 
marked loss of activity, as seen in compound 3.23. 
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Figure 3.5.3: Initial known SAR around the western section of the 3.15 lead series. 
With these data in mind, a second synthesis campaign was undertaken to explore the 
SAR around the 3.15 chemical scaffold at hmGlu1, starting with the eastern heterocycle.  Because 
3.15 and 3.20 had highly similar potencies at hmGlu1 and hmGlu4, we decided to begin our work 
with the unsubstituted phthalamide ring, and return to evaluate the western portion of the scaffold 
in a later library.   
 
Scheme 3.5.1: Synthetic scheme toward the library of 3.15-based hmGlu1 PAMs. 
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Using the chemistry highlighted in Scheme 3.5.1, we synthesized a 65 member library of 
analogs based on the 3.15 scaffold.  Beginning with nitro-analine 3.24, phthalamide cyclization 
was affected by refluxing with phthalic anhydride in glacial acetic acid for 18 hours.  The nitro 
group was subsequently reduced to the analine using tin(II) chloride in concentrated hydrochloric 
acid at 0o C.  With gram quantities of 3.26 in hand, the library was generated by employing 
HATU, diisopropylethylamine, and the corresponding heterocyclic carboxylic acid.  A wide 
range of eastern heterocycles were employed, starting with substituted 2-pyridine containing 
compounds and diversifying toward 3- and 4-pyridines, pyrimidines, pyrazines, and fused 
systems in the form of a quinolone (3.A in Figure 3.5.4).  We experimented with reduced ring 
size by employing variously substituted pyroles, pyrazoles and triazoles (3.B in Figure 3.5.4) and 
expanded nitrogen containing fused ring systems: indoles, indazoles, etc. (3.C in Figure 3.5.4).  
We also looked beyond nitrogen containing heterocycles by employing variously substituted 
imidazoles, furans, thiophenes, oxazoles, thiazoles, oxadiazoles, and bezofurans (3.D in Figure 
3.5.4) and some saturated heterocycles including tetrahydrofurans and tetrahydropyrans. 
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Figure 3.5.4: Eastern heterocycles employed in the 65 member library. 
The library was evaluated in Ca2+ fluorescence assays at 10 μM singlepoint concentration 
in order to triage for active PAMs.  Figure 3.5.5, Figure 3.5.6, and Figure 3.5.7 show the results 
of the three singlepoint screens.  In each of the screens, an effective concentration (EC20, EC22, 
and EC10, respectively) is noted on the far right.  Any compound that caused the glutamate 
response to climb above 50% of the maximum was deemed active enough to warrant further 
investigation. 
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Figure 3.5.5: Singlepoint screen (1 of 3 for 3.15 analog library) at 10 µM compound 
concentration against hmGlu1.  The asterisk denotes VU0405623 (3.15), the positive control for 
this experiment. 
 
 
Figure 3.5.6: Singlepoint screen (2 of 3 for 3.15 analog library) at 10 µM compound 
concentration against hmGlu1.   
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Figure 3.5.7: Singlepoint screen (3 of 3 for 3.15 analog library) at 10 µM compound 
concentration against hmGlu1.  The asterisk denotes VU0405623 (3.15), the positive control for 
this experiment. 
As the singlepoint screening data show, a total of 10 compounds successfully potentiated 
an EC20 dose of glutamate above 50% maximum response.  We deemed these PAMs active 
enough to warrant further investigation.  In order to determine potencies, concentration response 
curves were generated in triplicate and experiments were subsequently repeated on three separate 
dates for each active compound (Figure 3.5.8, Figure 3.5.9).   
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LogEC50
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EC50
VU0474482-1
14.30
100.1
-5.904
0.8249
1.246e-006
VU0474640-1
18.91
102.2
-5.887
0.9380
1.296e-006
VU0474567-1
18.84
107.3
-5.349
0.9534
4.475e-006
VU0474634-1
-0.3657
118.5
-7.184
0.7067
6.553e-008
VU0474712-1
17.74
92.75
-5.330
1.080
4.676e-006
VU0474633-1
3.180
118.6
-7.014
0.7352
9.688e-008  
Figure 3.5.8: Concentration response curves for 6 of the 11 active PAMs.   Curve fit data is 
shown, with EC50 values for each compound listed in the final row. 
Best-fit values
Bottom
Top
LogEC50
HillSlope
EC50
VU0475755-1
19.73
104.7
-6.138
1.069
7.285e-007
VU0475712-1
17.98
113.5
-6.262
0.9791
5.473e-007
VU0405623-1
-12.88
127.7
-7.503
0.5562
3.143e-008
VU0474405-1
17.40
109.4
-5.990
0.7139
1.023e-006
VU0474389-1
18.57
113.5
-6.196
0.7994
6.373e-007
VU0474394-1
20.94
89.84
-5.389
1.313
4.083e-006  
Figure 3.5.9: Concentration response curves for 5 of the 11 active PAMs, including VU0405623 
(3.15) as positive control.   Curve fit data is shown, with EC50 values for each compound listed in 
the final row. 
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At this point, the most active hmGlu1 PAMs were counterscreened against hmGlu4, in 
order to determine if a successful subtype selectivity switch was made.  Table 3.5.1 shows the 
counterscreening results.   
Table 3.5.1: Screening results for 10 active PAMs identified in the 65 member library. 
 
Collectively, these screening results informed us of several key elements of SAR around 
3.15: 1) the 2-position of the eastern heterocycle must be substituted with a strongly 
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electronegative atom.  All attempts at moving the nitrogen to the 3- and 4-positions resulted in a 
loss of activity.  Nitrogen was not the only option; oxygen was tolerated at the 2-position, as 3.22 
showed excellent potency at hmGlu1.  Additional substituted furans will be employed in further 
libraries.   2) The steric requirements of the system are somewhat more flexible as compared to 
the electronic requirements.  While more active PAMs were identified with six membered rings 
than five membered rings, the furan 3.22 proved to be the most potent compound at hmGlu1.  3) 
As has been observed with other allosteric modulators71, selectivity for one receptor subtype over 
another can be engendered by the addition of a single atom.  While 3.15 is highly potent at both 
hmGlu1 and hmGlu4, 3.19, which differs by the presence of a single methyl group and 3.20, 
which differs by a single chlorine atom, are both selective for hmGlu1 with no appreciable 
activity at hmGlu4.  Future libraries will explore the careful substitution of 2-pyridine and 2-furan 
systems. 
3.6 Schizophrenia Mutant Cell Line Studies 
While the singlepoint and CRC screening work was being conducted, Hyekyung Plumley 
in the Conn laboratory generated a collection of stable cell lines expressing the schizophrenia 
mutants identified in the previously discussed genetic studies.  These mutant cell lines were 
generated in the same tetracycline-inducible TREx293 cell background as wild type (WT) 
hmGlu1.   
When these mutant cell lines were analyzed in fold-shift Ca2+ response assays, they 
showed significantly decreased signaling compared to wild type hmGlu1. These findings are in 
good agreement with those of Ayoub and coworkers.  When both wild type and mutant cells were 
treated with 3.5 (VU0467832 in the below foldshift results) followed by increasing 
concentrations of glutamate, they showed a strong leftward curve shift, but no increase in 
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hepatic blood flow72.  Alternately, the CLHep value is calculated to predict the rate of in vivo 
clearance by the liver, taking into account hepatic blood flow rates and the efficiency of removal 
of presented drug.  As a result, CLHep values can never be greater than the rate of host hepatic 
blood flow.  In this instance, CLInt values are used to calculate CLHep values. 
This metabolism experiment was carried out by incubating test compound at 1 µM 
concentration in either human or rat liver microsomes containing cytochrome P450 (CYP) drug 
metabolizing enzymes and NADPH, a co-factor required for CYP activity.  As the compound was 
metabolized, its concentration decreases.  Concentrations of intact parent were measured over a 
45 minute time period by running the assay in parallel and quenching a certain number of wells 
on the plate (triplicate per timepoint) and analyzing by LCMSMS.  When the data is plotted using 
concentration of parent on Y-axis and time on X-axis, a line with negative slope is generated that 
provides a rate of metabolism, which is expressed as the half-life (t1/2) of the test compound.  This 
calculated t1/2 is then inserted into the equations below (Figure 3.7.2, Figure 3.7.1) in order to 
determine CLInt and CLHep. 
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ܥܮ′ூ௡௧	݉ܮ/݉݅݊/݇݃
ൌ 0.693	 ൈ	 1ݐ½	ሺ௠௜௡ሻ 	ൈ 	
1	݉ܮ
0.5	݉݃	݋݂	݌ݎ݋ݐ݁݅݊௠௜௖ 	ൈ 	
45	݉݃	݌ݎ݋ݐ݁݅݊௠௜௖
1	݃	ܮ݅ݒ݁ݎ	ݓ݄݁݅݃ݐ 	
ൈ	ሺܣሻ݃	݋݂	ܮ݅ݒ݁ݎ	ݓ݄݁݅݃ݐ݇݃	݋݂	ܾ݋݀ݕ	ݓ݄݁݅݃ݐ  
Where (A) is: 
Scale up factors (g liver / kg body weight) among different animal species commonly used: 
 Human    20* 
 Beagle Dog   25* 
 Cynomolgus Monkey  30* 
 Rat    45* 
 Mouse    87.5 
*Scaling factors were derived from Ref 73. 
 
Figure 3.7.1: Equation used to calculate intrinsic clearance (CLint) based on parent compound 
half-life (t1/2). 
 	
ܥܮுா௉	݉ܮ/݉݅݊/݇݃			 ൌ 	ܳு 	ൈ	ܥܮ௜௡௧ܳு ൅	ܥܮ௜௡௧ 	 
 
Where (QH) is: 
Hepatic blood flow for different animal species commonly used: 
 Human    21 
 Beagle Dog   31 
 Cynomolgus Monkey  44 
 Rat    70 
 Mouse    90 
 
Figure 3.7.2: Equation used to calculate hepatic clearance (CLHep) based on intrinsic clearance 
CLInt. 
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Table 3.7.1: VCNDD Tier 1 DMPK study with 3.15 and 3.5.  A * denotes that compounds were 
unstable in species plasma. 
Compound  3.15  3.5 
VU Number  VU0405623  VU0467832 
Structure 
    
Human 
CLint 
(mL/min/kg) 
210 262 
Human 
CLhep 
(mL/min/kg) 
19.1 19.4 
Rat 
CLint 
(mL/min/kg) 
166 661 
Rat 
CLhep 
(mL/min/kg) 
49.3 63.3 
Human 
PPB 
(Fu,p) 
* 0.003 
Rat 
PPB 
(Fu,p) 
* 0.014 
P450 
Inhibition IC50 
(µM) 
1A2  >30 13.0 
2C9  4.5 0.6 
2D6  >30 >30 
3A4  >30 >30 
2C19  - - 
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Table 3.7.1Both 3.5 and 3.15 featured hepatic clearance rates just under the human 
hepatic blood flow rate of 20 mL/min/kg (Table 3.7.1).  Theoretically, this value indicates that 
both compounds would be cleared from the body by the liver at a similar rate and would feature 
relatively short half-lives.  The intrinsic clearance rate of 3.15 was slightly lower at 210 
mL/min/kg compared to that of 3.5 at 262 mL/min/kg.  This indicates that 3.15 is metabolized 
slightly slower than 3.5 in an unrestricted system.  The same experiment carried out in rat liver 
microsomes revealed that 3.15 was metabolized significantly slower than 3.5, with CLHep values 
of 49.3 and 63.3 mL/min/kg, respectively, compared to rat hepatic blood flow rate of 70 
mL/min/kg.  Additionally, 3.15 featured a CLInt value of 166 mL/min/kg, compared to the 661 
mL/min/kg of 3.5.  Collectively, these clearance data show that the lead compound 3.15 is 
marginally better from a pharmacokinetics standpoint than the most potent and selective currently 
mGlu1 PAM.  Further clearance studies with a more optimized PAM will build on these initial 
findings.   
Table 3.7.1 also shows that 3.15 is unstable in both rat and human plasma.  The most 
likely sites of metabolism include the western phthalamide and the eastern amide, which could 
both be hydrolyzed by esterase enzymes in plasma.  Similar instability has been found in the 
Daniels laboratory recently with succinimides, which are close structural relatives to 
phthalamides.  Metabolite identification experiments are currently underway to determine the 
metabolic liability on this compound.  Additional SAR work around the western portion of the 
molecule is planned to address this concern.  As a comparison, 0.3% of compound 3.5 exists 
unbound in human plasma and 1.4% exists unbound in rat plasma.   
The final set of drug metabolism experiments involved cytochrome P450 enzyme 
inhibition analysis.  Of the 4 CYP enzyme subtypes studied, 3.5 and 3.15 were almost entirely 
inactive at all but one subtype.  While 3.5 features an IC50 value of 600 nM at CYP 2C9, 3.15 has 
a greater than 2-fold higher IC50 value of 4.5 µM at the same enzyme.  These data show that CYP 
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inhibition would likely not be a major source of concern if the 3.15 scaffold were carried forward 
into animal models.    
Overall, these experiments showed that, while there is an initial question of compound 
stability, 3.15, is a strong lead for further optimization toward the development of a potent and 
selective mGlu1 PAM.  In the short term, because the goal of this project is to develop a new tool 
compound to study mutant receptor cell lines in vitro, the high clearance values in human and rat 
are not immediately detrimental to the chemical series.  A similar comment can be made about 
the CYP inhibition.  The plasma/protein binding instability does raise some concerns, though the 
structural liabilities will be addressed in future libraries of analogs.  The CYP inhibition data is 
highly encouraging and offers an early indication that ancillary pharmacology may not be a major 
concern in the future for this scaffold, though additional experiments similar to the panel screens 
run in Chapters I and II will reveal more along these lines. Finally, these drug 
metabolism/pharmacokinetics studies represent an initial glance into the profile of the 3.15 
scaffold.  A strong DMPK profile was achieved in this series in hmGlu4 and it remains a goal for 
the future work at hmGlu1.   
3.8 Conclusion 
Pedro Garcia, a first year graduate student who recently joined the Lindsley laboratory, has 
carried this work forward in recent weeks.  He has confirmed all of the human mGlu1 screening 
data by repeating the experiments in the rat mGlu1 cell line and has synthesized an additional 
focused library of analogs around 3.15 and 3.24, the most selective hmGlu1 PAM.  The rat 
screening data has shown that the active PAMs at the human receptor show similar potencies at 
the rat isoform.  Garcia’s most recent library built on the SAR that we determined from the 
previous 65 member library.  The eastern 2-pyridine was methodically probed with halogen and 
methyl substituents around the 3, 4, and 5 positions of the ring.  From this work, a highly potent 
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PAM (more potent that 3.5 at rmGlu1) has been identified.  This new compound is now the most 
advanced mGlu1 PAM lead. Figure 3.8.1 shows some of the planned libraries that will be 
generated around the 3.15 scaffold. 
 
Figure 3.8.1: Potential sites of SAR development around the 3.15 scaffold to be investigated in 
the future.   
Additional experiments have been planned moving forward: concentration response 
curves for the various mutant cell lines will be generated using the most advance PAM lead 
compound alongside 3.5 and 3.15 as positive controls.  The differences in Ca2+ signaling in the 
mutant and wild type cells could be attributed to receptor reserve issues.  In this matter, we will 
take advantage of the tetracycline-inducible system of our cell lines.  The receptor expression 
level will be controlled by treating cells with varying doses of tetracycline and the Ca2+ signaling 
response will be measured.  In addition, saturation binding experiments will be conducted directly 
to measure the receptor expression level.  These experiments will be done in collaboration with 
the Conn laboratory and the VCNDD.   
This work represents the first series of investigations by our laboratory into a centrally 
penetrant, potent, and selective positive allosteric modulator of human mGlu1.  While the VU-
71/48 (3.6/3.7) series ultimately proved unproductive, the 3.15 series has already shown great 
promise and will continue to be the focus of the project moving forward.     
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EXPERIMENTAL METHODS 
 
Synthesis: 
All reagents were purchased from Sigma‐Aldrich Corp., Matrix Scientific, Fisher 
Scientific, and Ark Pharm Inc., and were used without purification. Analytical thin‐layer 
chromatography (TLC) was performed on 250 μm silica gel plates from Sorbent Technologies. 
Visualization was accomplished via UV light, and/or the use of ninhydrin, I2, 2,4-
dinitrophenylhydrazine, and potassium permanganate solutions followed by application of heat. 
Chromatography was performed using Silica Gel 60 (230‐400 mesh) from Sorbent Technologies 
or Silica RediSep Rf flash columns on a CombiFlash Rf automated flash chromatography system. 
Low resolution mass spectra (LCMS) were obtained on an Agilent 1200 LCMS with electrospray 
ionization. High resolution mass spectra (HRMS) were recorded on a Waters Qtof‐API‐US plus 
Acquity system with ES as the ion source. Analytical high pressure liquid chromatography 
(HPLC) was performed on an Agilent 1200 analytical LCMS with UV detection at 214 nm and 
254 nm along with ELSD detection.  
 
3-oxo-2-phenylpropanenitrile 3.8.  
A 500 mL 3 neck schlenk flask was fitted with a stirbar and condenser.  The flask was flame 
dried and vacuum purged with argon 3X.  The flask was then charged with 3.82 g (0.166 mmol) 
sodium and then repurged with argon 3X.  EtOH (150 mL) was added and the flask is stirred until 
the sodium was consumed.  Phenyl acetonitrile (15 g, 0.128 mmol) was added and the flask was 
stirred 5 minutes, followed by ethyl formate (15.44 mL, 0.921 mmol).  The reaction was brought 
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to reflux for 2 hours.  Product formation was confirmed by LCMS.  The reaction mixture was 
then cooled and concentrated under reduced pressure.  The resulting organics were then 
partitioned between EtOAc (50 mL) and H2O (50 mL).  The organic phase was then dried over 
MgSO4, filtered, and concentrated.  The product was purified on silica (1:1 EtOAc:Hex), yielding 
11.6 g (62%) 3.8.  Product mass confirmed by LCMS. 
 
General procedure for synthesis of 4-substituted amino-pyrazoles (3.10). 
A large size microwave vial was charged with a stirbar and 3.8 (500 mg, 3.44 mmol) and a 
corresponding hydrazine (3.44 mmol).  EtOH was added (10 mL) and the vial was sealed.  The 
vial was heated in the microwave reactor at 160oC for 30 min.  Product formation was judged by 
LCMS.  The resulting aminopyrazole was then passed through a silica plug, washing with EtOAc, 
and carried forward crude. 
 
General procedure for synthesis of 3-substituted amino-pyrazoles (3.13). 
A large size microwave vial was charged with a stirbar and 3.12 (500 mg, 3.44 mmol) and a 
corresponding hydrazine (3.44 mmol).  EtOH was added (10 mL) and the vial was sealed.  The 
vial was heated in the microwave reactor at 160oC for 30 min.  Product formation was judged by 
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LCMS.  The resulting aminopyrazole was then passed through a silica plug, washing with EtOAc, 
and carried forward without further purification. 
 
General procedure for synthesis of 75 member library around 3.6/3.7 scaffolds. 
A microwave vial was charged with a stirbar, either 3.10 or 3.13 (0.185 mmol), PyClU (0.20 
mmol), the corresponding heterocyclic carboxylic acid (0.20 mmol) and 3 mL of a premixed 9:1 
solution of CH3CN: iPr2NEt.  The vial was then sealed and heated in the microwave reactor at 
160o C for 30 minutes. After heating, each sample was analyzed by LCMS to determine product 
formation.  DCM (2 mL) and H2O (2 mL) were then added to each tube.  The tubes were 
resealed, shaken vigorously, and then the contents were passed through a phase separator 
(Isolute).  The organic phase was then concentrated on drying blocks, before being redissolved in 
DMSO (1 mL).  Products were then purified using reverse phase high performance liquid 
chromatography, affording sixty five compounds (10-80% total yield) as TFA salts when 
applicable with >98% purity. 
 
2-(2-chloro-4-nitrophenyl)isoindoline-1,3-dione (3.25). 
A 100 mL round bottom flask was charged with a stir bar, 10 g (57.94 mmol) 2-chloro-4-
nitroaniline (3.24), 12.8 g phthalic anhydride, and 25 mL glacial acetic acid.  A reflux condenser 
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was added and the flask was heated to reflux for 18 hours.  The reaction was monitored by TLC.  
Upon completion, the flask was removed from heat and allowed to cool to room temp.  H2O was 
added (50 mL) and the flask was stirred for approximately 30 min.  After stirring in H2O, a solid 
precipitated out of solution.  The flask contents were then poured over a Buchner funnel fitted 
with filter paper.  The bright yellow solid precipitate was then washed with 2 L H2O, yielding the 
product 3.25 as an off white solid.  The product was then subjected to high vacuum for 12 hours 
until dry.  Obtained 12.56 g (71%) 3.25 as an off white solid, product confirmed by LCMS.   
 
2-(4-amino-2-chlorophenyl)isoindoline-1,3-dione (3.26). 
A 250 mL round bottom flask was charged with a stirbar, 2.43 g (8.02 mmol) of 3.25, and 40 mL 
dioxane, before being cooled to 0o C. A separate flask was charged with 7.6 g (40.1 mmol) SnCl2 
and 13.4 mL conc. HCl..  The SnCl2 was stirred until completely dissolved and then added 
dropwise to the cooled flask containing starting material. The reaction was stirred 20-30 minutes, 
monitoring by TLC for consumption of starting material.  Upon completion, the reaction was 
quenched by raising the pH of the acidic solution with 1 N NaOH to roughly pH 6 (~120-150 mL 
1N NaOH).  Once the pH was sufficiently elevated, a precipitate formed.  The precipitate was 
filtered off using a fine grain glass fritted funnel, washing with dichloromethane.  The resulting 
organic solution was then concentrated and purified on silica (1:1 EtOAc:Hex), yielding 1.96 g 
(89%) 3.26 as a light yellow solid, confirmed by LCMS. 
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General procedure for hmGlu1 library around 3.15 scaffold.  
Each of 65 test tubes (13x100 mm) was fitted with a stir bar, and 20 mg (0.073 mmol) 3.26.  The 
corresponding heterocyclic carboxylic acid was added (roughly 15-20 mg as the excess reagent) 
and 40 mg (0.11 mmol) HATU.  Approximately 2 mL of a premixed 9:1 DCM:iPr2Net solution 
was then added.  Each test tube was sealed with a plastic stopper and stirred at room temperature 
for 12 hours.  After stirring, each sample was analyzed by LCMS to determine product formation.  
DCM (1 mL) and H2O (2 mL) were then added to each tube.  The tubes were resealed, shaken 
vigorously, and then the contents were passed through a phase separator (Isolute).  The organic 
phase was then concentrated on drying blocks, before being re-dissolved in DMSO (1 mL).  
Products were then purified using reverse phase high performance liquid chromatography, 
affording sixty five compounds (15-85% total yield) as TFA salts when applicable with >98% 
purity. 
Mutagenensis: 
Human mGlu1 WT cDNA was cloned into tetracycline-inducible expression vector, hmGlu1-
pcDNA5/TO. All schizophrenic mutant plasmids were generated by site-directed mutagenesis in 
hmGlu1-pcDNA5/TO using QuickChange II mutagenensis kit (Agilent). All point mutations were 
confirmed by sequencing.  In order to generate stable cell lines, each expression plasmid was 
transfected into TREx293 cells stably expressing Tet Repressor.  Cells were then subject to 
hygromycin selection for 2 weeks. The resulting hygromycin-resistant cells were examined in 
Ca2+ assay to ensure the function of mGlu1 protein, Gq-coupled Ca2+ response. 
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Ca2+ Fluorescence Assays: 
For all FDSS screens/assays, cells (10,000 cells/20 μl/well) were plated in blackwalled, clear-
bottomed, poly-D-lysine treated, 384 well plates (Greiner Bio-One, Monroe, North Carolina) in 
Ham’s F12 medium supplemented with 10% FBS and 20 mM HEPES. The cells were grown 
overnight at 37° C in the presence of 5% CO2. The next day, the medium was removed and 
replaced with 20 μl of 2 μM Fluo-4AM in calcium assay buffer (Hank’s Balanced Salt Solution 
supplemented with 20 mM HEPES and 2.5 mM Probenecid) and the cell plates incubated for 60 
minutes at 37 °C. Dye solution was removed and replaced with 20 μl of fresh assay buffer. Test 
compounds were transferred from a 384-well source plate (10 mM DMSO, 30 μl/well) to 384-
well daughter plates using an ECHO acoustic plate reformatter (Labcyte) and then diluted into 
assay buffer to 20 μM stock concentration (2X). Glutamate (Aldrich) was diluted in a 384-well 
plate containing submaximal (~EC20, determined empirically) and maximal (10 μM) stock 
concentrations (5X). Mobilization of intracellular calcium was measured using the Functional 
Drug Screening System 6000 (FDSS6000, Hamamatsu). Baseline readings were taken and then 
test compounds (30 μM final, 20 μl/well) were added using the FDSS’s integrated pipettor. After 
150 seconds of equilibration, glutamate (EC20 and maximal concentrations, 10 μl/well) was 
added using the FDSS’s integrated pipettor. Data were obtained as max-min fluorescent ratios 
and then normalized to percentage of maximum Glu response and represent mean values obtained 
from three independent determinations (error bars represent +/- SEM) unless otherwise specified.  
For Flexstation screens/assays methods used were in a format similar to those described above 
using the same reagents. TREx293 cells stably expressing Tet Repressor and hmGlu1 were plated 
in 100 mL of growth medium 8x104 cells per well in poly-D-lysine coated Costar 96-well black-
walled, clear-bottom plates (Fisher).  Cells were incubated overnight at 37 °C under 5% CO2. 
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The next day, medium was removed from the cells, and they were incubated with 50 mL of 2 mM 
Fluo-4 AM diluted in assay buffer for 1 h at 37 °C. Dye was then removed and replaced with 45 
mL of fresh assay buffer. Test compounds were diluted in assay buffer at 2X concentration and 
glutamate was diluted in assay at a 10X concentration. FLEXstation II (Molecular Devices) 
automated plate reader was used for assay execution and measurement of calcium flux. After 
establishing baseline fluorescence, test compounds (45 mL) were added to the cells using the 
FLEXstation II’s integrated pipettor and allowed to equilibrate for 150 seconds before addition of 
glutamate (10 mL). Data were obtained as max-min fluorescent ratios and then normalized to 
percentage of maximum Glu response. For test compounds exhibiting intrinsic fluorescence 
(typically found only at 30 μM final), adjustment of analysis time window for max-min values 
was sometimes performed in order to obtain more accurate baseline readings. Calculation of 
potentiation EC50 was performed using the curve-fitting software GraphPad Prism (version 4.0c). 
Data shown represent mean values obtained from at least three independent determinations 
performed in triplicate or greater (error bars represent +/- SEM) unless otherwise specified.  
Drug Metabolism/Pharmacokinetics: 
Microsomal Stability: 
The metabolic stability of each compound was investigated in human and rat hepatic microsomes 
(BD Biosciences, San Jose, CA) by using substrate depletion methodology (percentage of parent 
compound remaining). In separate 96-well plates for each time point, a mixture of 0.1 M 
potassium phosphate-buffered, pH 7.4, 1 µM test compound, 0.5 mg/ml microsomes, and 1 mM 
NADPH (t = 3, 7, 15, 25, or 45 min) or buffer (t = 0) were continually incubated at 37°C under 
ambient oxygenation. At the respective time, each plate’s reaction was precipitated by the 
addition of 2 volumes of ice-cold acetonitrile containing glyburide as an internal standard (50 
ng/ml). The plates were centrifuged at 3000 rpm (4°C) for 10 min. The resulting supernatants 
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were transferred and diluted 1:1 (supernatant/water) into new 96-well plates in preparation for 
LC/MS/MS analysis. Each compound was assayed in triplicate within the same 96-well plate. 
The in vitro half-life (t1/2, min), intrinsic clearance (CLint, ml/min/kg), and subsequent predicted 
hepatic clearance (CLHEP, ml/min/kg) was determined by using the following equations t ½ = 
Ln(2)/k where k represents the slope from linear regression analysis (percentage of test 
compound remaining) and equations listed in Figure 3.7.1 and  Figure 3.7.2. 
Plasma Protein Binding:  
The protein binding of each compound was determined in human and rat plasma via equilibrium 
dialysis of mGlu4 PAM using Single-Use RED Plates with inserts (Thermo Fisher Scientific, 
Waltham, MA). Plasma (220 µl) was added to the 96-well plate containing test compound (5 µl) 
and mixed thoroughly.  Subsequently, 200 µl of the plasma-compound mixture was transferred to 
the cis chamber (red) of the RED plate, with an accompanying 350 µl of phosphate buffer (25 
mM, pH 7.4) in the trans chamber.  The RED plate was sealed and incubated for 4 hours at 37° C 
with shaking.  At completion, 50-µl aliquots from each chamber were diluted 1:1 (50 µl) with 
either plasma (cis) or buffer (trans) and transferred to a new 96-well plate, at which time ice-cold 
acetonitrile (2 volumes) was added to extract the matrices. The plate was centrifuged (3000 rpm, 
10 min) and supernatants were transferred and diluted 1:1 (supernatant/water) into a new 96-well 
plate, which was then sealed in preparation for LC/MS/MS analysis. Each compound was assayed 
in triplicate within the same 96-well plate.  
CYP450 Inhibition:  
A four-in-one, 96-well plate assay for determining IC50 values against human CYP450 1A2, 
2C9, 2D6, and 3A4 was developed based on previous reports (Youdim et al., 2008).  Human liver 
microsomes (final concentration of 0.1 mg/ml) and a substrate mixture containing the CYP450 
probe substrates phenacetin (10 µM), diclofenac (5 µM), dextromethorphan (5 µM), and 
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midazolam (2 µM) were added to a potassium phosphate-buffered solution (0.1 M, pH 7.4) and 
warmed to 37°C. The reaction mixture was divided evenly into the 96-well plate, and various 
dilutions of each inhibitor/compound of interest (in duplicate) were then added to this reaction 
mixture such that the final concentration of each compound ranged from 100 nM to 30 µM. This 
mixture was allowed to preincubate for 15 min while shaken at 37°C. Buffer or NADPH (1 mM) 
was added, and the reaction mixture was incubated for an additional 8 min at 37°C before 
quenching with 2 volumes of ice-cold acetonitrile containing 50 ng/ml of carbamazepine as 
internal standard.  The plates were centrifuged at 4000 rpm (4°C) for 10 min, and the supernatant 
was removed and diluted with water (1:4, v/v) in preparation for LC/MS/MS analysis. The IC50 
values for each compound were obtained for the individual CYP450 enzymes by quantitating the 
inhibition of metabolite formation for each probe: acetaminophen (1A2), 4-hydroxydiclofenac 
(2C9), dextrorphan tartrate (2D6), and 1-hydroxymidazolam (3A4). Miconazole was included as 
a positive control broad-spectrum CYP450 inhibitor. For discrete 2C19 inhibition experiments, a 
similar assay design was used with the following exceptions: the probe substrate was S-
mephenytoin (40 µM), the NADPH incubation with the reaction mixture went for 30 min, the 
supernatant was reconstituted 1:1 with water for analysis, and the metabolite used for quantitation 
was 4-hydroxymephenytoin.  
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Spectra Relevant to Chapter I 
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Spectra Relevant to Chapter II 
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